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Abstract 
This thesis employed a stem cell encapsulating hydrogel patch to increase the 
amount of beneficial soluble factors that are delivered to the surface of damaged 
heart tissue following a myocardial infarction. While current medical practices to 
address the immediate aftermath of a myocardial infarction (MI) have evolved 
tremendously, there are few, if any, techniques currently administered to slow, 
cease, or reverse the negative side effects of an occluded artery, such as the 
replacement of functional myocardium with non-contractile scar tissue. Because 
of this scar formation, survival of the initial heart attack is commonly 
accompanied by a decrease in left ventricular functioning due to wall thinning and 
ventricular enlargement. As a result of the slow, or absent, ability of 
cardiomyocytes to divide and repopulate the infarcted area, the burden of heart 
function lies on the surrounding tissue; a load that exhausts the healthy tissue 
and decreases the quality of life of heart attack survivors. 
Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic 
avenue for post-MI treatment, in part due to the “survival signals” that they 
secrete. Previous work has shown that by increasing the amount of “survival 
signals” that are introduced to the damaged myocardium, the extent of 
cardiomyocyte cell death, and subsequent scar formation, can be decreased. 
While the therapeutic effects of these factors have been documented, one 
difficulty lies in the ability to maintain a constant flux of secreted factors to the 
damaged site. This project hypothesized that through the encapsulation of stem 
cells within an engineered hydrogel construct, the hurdle of soluble factor 
delivery at the site of injury could be overcome. A constant flux of paracrine 
factors to the heart surface would allow for cell recruitment to the site(s) of 
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damage, prevention of tissue degradation due to inhospitable environments, and 
promotion of neovascularizion for sustainable tissue regeneration. 
Using both a chick chorioallantoic membrane assay and a mouse model of MI, 
the following aims determined: 1) the vascularization potential of an MSC 
encapsulated patch, 2) the ability to deliver hydrogels containing pro-survival 
signals to the heart post-MI, and 3) the ability of these factors to decrease scar 
formation and improve cardiac function following a heart attack. Knowledge 
gained from this project will provide the basis for designing materials and 
strategies for similar studies in larger animal models and eventually for human 
clinical trials. Successful delivery of the MSC encapsulating patch, and 
subsequent decrease in myocardial degradation, will greatly improve the quality 
of life scores of individuals who have suffered heart failure. This increase in 
quality of life will aid in post-MI mobility and decrease the need for more intensive 
health care following the initial heart attack; overall decreasing the burden a 
strained heart has on both patients and the healthcare system. 
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1. INTRODUCTION 
 
1.1 Motivation and hypothesis 
The objective of this thesis was to introduce a stem cell encapsulating hydrogel 
patch onto the surface of a damaged heart to prevent the degradation of tissue 
following a myocardial infarction (MI). An MI is defined as the occlusion of blood 
flow to a portion of the heart due to the rupturing of an atherosclerotic plaque. 
The lack of oxygen and nutrients delivered to the tissue presents an environment 
that is insufficient for proper tissue viability and remodeling. Within as little as 48h 
following occlusion, the extracellular matrix of the tissue begins remodeling and 
non-contractile scar tissue replaces functioning myocardial tissue, interfering with 
the ability of the heart to function properly. Mesenchymal stem cells (MSCs) have 
emerged as an encouraging therapeutic avenue shown to decrease tissue 
damage, increase cardiac output and promote vasculogenesis following acute 
myocardial infarction. Although such results are promising, current clinical 
delivery methods do not ensure MSC retention within the injured tissue. This 
research aims to overcome this critical barrier through the encapsulation of 
MSCs within a hydrogel patch using a specially modified Stereolithographic 
Apparatus (SLA). Previous work has shown that when the SLA is used to 
introduce microchannels into a fibroblast encapsulating hydrogel patch, 
neovessels were observed to correlate with microchannels, demonstrating 
controlled and directed neovascularization. This study was based on these 
promising results, with the motivation to keep the ischemic tissue alive long 
enough for angiogenesis to occur. We hypothesized that through the formation of 
a cell encapsulating hydrogel patch, cell to tissue interactions can be maintained 
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over a physiologically relevant time course, decreasing the damage caused by a 
myocardial infarction and increasing angiogenesis in a directed manner.  
 
1.2 Overview and specific aims 
This approach was centered on three major aims: 
Aim 1: Optimize MSC suspension in SLA patterned hydrogels to ensure long-
term survival of encapsulated cells. As stated, preliminary data demonstrate that 
fibroblasts remain viable for up to 7d within a poly (ethylene glycol) 
dimethacrylate (PEGDMA) hydrogel patch, secreting beneficial soluble factors to 
the surrounding media or tissue. This same method of encapsulation will be 
applied to MSCs with the objective of providing an optimal environment within the 
hydrogel patch for long-term MSCs viability.  
 
Aim 2: Deliver encapsulated MSCs and supporting cells to the surface of 
infarcted tissue to ensure cell to tissue contact over extended time course. 
Adhesion of a patch to the heart, with minimal residual damage, requires the 
formulation of a glue able to maintain patch-to-tissue fusion, and malleable 
enough not to interfere with heart function. The glue must be proven to be 
biocompatible with both the myocardium and the encapsulated cells. The use of 
this developed glue will permit maintenance of the hydrogel construct at the site 
of injury, ensuring its healing potential at the ischemic area. 
 
Aim 3: Validate the beneficial properties of cell encapsulation in vivo through the 
establishment of a murine myocardial infarction model. To provide a test model, 
we will compile and modify murine myocardial infarction techniques from a 
number of established protocols and implement a procedural model. In order to 
test the efficiency of the model and ensure proper infarction damage, the 
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degradation of the myocardium will be assessed and the differences in treatment 
methods will be determined.  
 
By accomplishing these aims of providing a means of encapsulating cells in a 
patch and placing that patch directly on the heart surface, a constant influx of 
paracrine factors to the ischemic tissue can be maintained over a suitable time 
course. The delivery of encapsulated cells to the surface of infarcted tissue for an 
extended period of time has proven to decrease or slow the degradation process 
while at the same time increasing angiogenesis, possibly in a directed manner. If 
demonstrated as clinically translatable, a new therapeutic avenue can be 
established that revolves around a non-toxic, immune friendly patch that delivers 
soluble factors to the site of injury. 
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2. BACKGROUND AND LITERATURE REVIEW 
 
2.1 The Heart 
The entire physiological balance of any living animal centers on the proper 
functioning of a single organ, the heart. The regular beating of the heart provides 
the body with a steady supply of nutrients and oxygen, without which would 
cause a total shutdown of all vital organs. The heart’s pumping action is 
accomplished by the collective beating of the organ-specific muscle cells, known 
as the cardiomyocytes, which, when taken together, form the myocardium, or 
cardiac muscle. Contraction of the cardiomyocytes occurs during the phase of 
the cardiac cycle known as systole, while relaxation, and subsequent re-filling of 
the heart chambers is a phase termed diastole. It is this constant circulation of 
systole and diastole that results in movement of the blood throughout the entire 
cardiovascular system1.  
 
The chamber of the heart that is responsible for the force required to pump blood 
out of the heart and into the peripheral system is the left ventricle (LV), which, 
consequently, is the chamber that is most prone to cardiac dysfunction. The 
myocardium itself requires blood flow to maintain proper functioning, which is 
obtained through its own vascular system, the coronary vessels. It is an 
obstruction of these vessels that leads to one of the greatest causes of mortality 
worldwide, myocardial infarctions (MIs)2. The interruption of blood flow results in 
cell death at the site of ischemia, which is later replaced by non-functional scar 
tissue3. An interference with the functioning of the heart ultimately has systemic 
physiological consequences for the rest of the body, one of the major reasons 
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why cardiovascular disease is such a major hindrance on the overall health and 
well being of the world population4. 
 
2.2 The Effect of CVD on the Body 
Cardiovascular disease (CVD) is defined as pathological conditions that affect 
any aspect of the vascular system, including the heart, pericardium, and blood 
vessels. CVD is a far-reaching term, encompassing a wide range of etiologies 
including cardiac dysrhythmia, myocarditis, peripheral arterial disease, and 
coronary artery disease. Although it a broad-encompassing disease, there are 
very similar sources associated with it, with the most common being 
atherosclerosis and high blood pressure5.  In fact, hypertension was determined 
to be the biggest contributor to the global burden of disease and to global 
mortality, in part due to its close ties with it accompanying risk of CVD and its 
debilitating side effects6.  A large-scale analysis on over 83,000 presenting cases 
of CVD encompassing 12 distinct presentations showed a distinct increase in the 
lifetime risk of each type of CVD with an increase in patient hypertension7. 
 
As with most major diseases, CVD has systemic implications. For example, the 
narrowing of the peripheral vessels, also known as peripheral artery disease 
(PAD), may cause immense pain that can limit walking, decreasing the patient’s 
ability to exercise, usually resulting in an increase in fat deposition and obesity 
and an accompanying decrease in possible interventions that might help with the 
patient’s overall health and well being. In some instances, the decrease in blood 
flow to an extremity may result in ischemia so severe it may require intervention 
in the form of amputation8.  Additionally, patients presenting with PAD have a 4 
to 5 times higher risk of cerebrovascular events such as a stroke9. The systemic 
implications, and secondary complications, make CVD a long-term disease that 
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is difficult to manage from a clinical perspective, and difficult to live with from a 
patient perspective. 
 
One of the major players in CVD is coronary heart disease and, more 
specifically, MIs. Coronary heart disease is one of the leading causes of mortality 
in the United States, accounting for approximately one in every six deaths. It has 
been calculated that an American has a coronary event every 25s, with a death 
occurring approximately every minute of the day10. Progressive buildup of plaque 
within the walls of a coronary artery eventually leads to total occlusion of the 
blood flow through the affected artery. This cessation of blood flow is what is 
defined as an MI one of the major contributors to CVD. Physiological changes 
begin to occur almost immediately following the vessel blockage, due almost 
entirely to the inability of the affected heart muscle to properly beat without the 
necessary nutrient and oxygen supply. From a symptomatic standpoint, a patient 
enduring an acute MI will have a sudden onset of chest pain, usually 
accompanied by a tingling or painful sensation running down their left arm. 
Patients sometimes feel fatigued and short of breath preceding the event. Within 
the heart itself, the myocardial tissue begins to remodel, replacing viable cells 
with a fibrous scar tissue11,12. The changes in the heart tissue begin almost 
immediately following occlusion, and remodeling itself lasts for months after the 
initial assault. There are many factors that play a part in the response 
mechanism of an MI, some of which will be highlighted in the following section. 
 
2.3 Timeline of Irreversible Myocyte Necrosis Following an MI Injury 
2.3.1 Cellular view of cardiomyocyte death 
A cellular view of myocardial infarction begins with fast accumulation of 
potassium in the extracellular fluid within 20s post-infarction and plateaus after 3-
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10min. This rapid increase in potassium is due to a disturbance in the 
sodium/potassium pump that is involved in actively keeping intracellular 
potassium levels high and extracellular potassium levels low. After 20-30min of 
continuous ischemia, a second, larger increase in potassium is seen in the 
extracellular space, a phase that correlates to the beginning of irreversible 
myocyte death13. At around the same time as the secondary potassium spike, 
enzymes associated with cardiac function, including glutamic oxaloacetic 
transaminase and succinic dehydrogenase, can be detected extracellularly, 
another determinate of myocyte degradation14. Homogenized myocardial tissue 
taken 30m post-infarction showed a decrease in its oxidative metabolism ability, 
reinforcing that the death of myocytes begins as early 30m post-infarction15.  
 
From a pathophysiological perspective, the remodeling of the heart after an MI 
begins within min, with irreversible cell death occurring within 6h, and total 
remodeling occurring over the course of months. In a canine study aimed to 
determine the degree and timing of irreversible cell injury, the coronary arteries of 
animals were blocked for a varying amount of time, at which point they would be 
reopened and reperfusion was allowed to occur. Irreversible cell death was 
denoted as cells that exhibited swelling, mitochondrial calcification, prominent 
contraction bands, and membrane disruption upon the re-introduction of blood 
flow, a term denoted as contraction band necrosis (CBN)16. It was observed that 
cells were able to fully recover to their pre-ischemic state if the occlusion of the 
artery lasted for 15min or less. After 15min, cell death began, with an increase in 
death as time progresses. Most CBN occurs over a 3h period, with total CBN 
development at 6h17. Interestingly, necrosis begins as a wave beginning with the 
inner layer of the heart and gradually proceeding to the outer layers, owing to the 
fact that the outer layers still receive some blood flow from neighboring vessels, 
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whereas layers closer to the chamber are left without nutrients and oxygen 
supply. This gradient of necrosis is attributed to arterial collateral flow that is 
higher in the outer layers and decreases as you move closer to the ventricular 
chambers18. If animals are left to live, areas that display CBN eventually remodel 
into scar tissue despite the re-introduction of blood flow to the area19. Thus, there 
is a timeframe of 0-6h in which interventional therapy will have an effect on 
slowing the degradation of functional cardiac muscle into scar tissue. 
 
2.3.2 Morphological changes following myocardial infarctions 
On a gross morphological evaluation, all myocardial infarctions show the same 
characteristic progression of coagulative necrosis, followed by acute, then 
chronic inflammation, and finalized by fibrosis at the site of injury. At 12h post-
infarction, there is usually no gross morphology that can positively identify a 
myocardial infarction, however, by 3h an infarct can be seen with Tetrazolium 
chloride, a stain that identifies areas of decreased enzyme activity, implicating 
the depletion of enzymes at the site of damage. Gross identification does not 
occur until 12-24h post-infarction, when a red-blue discoloration associated with 
coagulated blood due to a decrease of blood flow in the area1-3.  
 
The coagulative necrosis that is displayed in MIs is a type of necrosis in which 
the underlying tissue architecture is preserved, but cells begin their deterioration. 
While the cell structure and morphology remains in tact, the organelles, 
specifically the cell nuclei, begin to disappear. Enzyme denaturation 
accompanies structural protein breakdown, and inflammatory cells are recruited 
to the site to aid in the digestion of dead cells. This entire process usually begins 
at 4h post-infarction and lasts for approximately 3d. During this time, 
cardiomyocytes begin to lose their striations and begin to take on a wavy 
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appearance with edema present between necrotic cells. After approximately 14d, 
cardiomyocytes begin to be replaced with a loose connective tissue that provides 
the scaffold for eventual collagen deposition. The scar tissue begins to form at 
2wk, with a dense collagenous scar and final fibrosis seen at 8wk post-infarction 
(Table 2.1)1. Histologically, scar tissue can be identified by Masson’s Trichrome 
staining as a light blue or deep purple color that denotes collagen and fibrin at 
the site of injury. Fibrous scarring begins on the border zone, or edge, of the 
infarct region, and progresses inwards until the entire ischemic area is remodeled 
into non-functional scar tissue20. The heart was always thought of as a terminal 
organ, with a fixed number of cardiomyocytes from birth and an inability to 
regenerate lost muscle tissue, however, recent evidence suggests repopulation 
can occur under the proper circumstance, opening up a field of tissue 
regeneration and stem cell therapy that was once thought impossible21. 
 
2.4 Stem cell therapy to treat CVD 
2.4.1 Clinical Trials 
It is clear that CVD is a major overall public health issue. Early interventions must 
be implemented to help curb its onset and the debilitating side effects that CVD 
causes. Along with preventative measures, a number of interventional, stem cell 
based, therapeutics might aid in preventing the decrease of function that 
accompanies CVD events. Initial promise in laboratory studies resulted in a rapid 
onset of clinical trails to test the efficacy of stem cell treatments22. 
 
One of the major cornerstones in stem cell therapy for the treatment of MIs was 
the Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute 
Myocardial Infarction (REPAIR-AMI) clinical trial, a study that ran from 2004 to 
2010. The REPAIR-AMI trial focused on the intracoronary delivery of bone-
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marrow derived progenitor cells (BMCs) in 204 randomized patients with acute 
MI. Delivery of stem cells was done 3-7d post-reperfusion and patients were 
followed for up to 2yr. After 4min an enhanced contractive recovery of left 
ventricular function was observed, as well as a significantly greater improvement 
in regional contractility in the treated groups versus those of the placebo23. When 
examined 2yr after the treatment, there was a significant change in recurring MIs, 
with an observation of 0 in the BMC treated group and a total of 12 in the placebo 
group, albeit some of those were multiple recurrent MIs. There was also a 
significant reduction in infarct size and regional contractility. Interestingly, at 2yr, 
there was a slight improvement in LVEF, but not as marked as at 4mo23-25. 
 
A similar trial, termed the BOne marrOw transfer to enhance ST-elevation infarct 
regeneration (BOOST), was conducted in 2002. This randomized-control trial 
delivered intracoronary injection of autologous BMCs 3-6d post percutaneous 
coronary intervention in 60 patients. In contrast to the REPAIR-AMI trail, the 
BOOST trial showed no significant improvement in LVEF, but it did report an 
initial improvement in diastolic function at 6mo and 18mo post-treatment, a 
parameter not reported on in the REPAIR-AMI trial26. The diastolic improvement 
diminished at 60mo post treatment, concluding that there was no sustained effect 
on the long-term follow-up of patients 27. 
 
A more recent clinical trial involving autologous cardiac stem cells began in 2009 
and is still ongoing. Stem Cell Infusion in Patients with Ischemic cardiomyopathy 
(SCIPIO) expanded autologous cardiac stem cells in culture and delivered them 
via intracoronary infusion 113d after coronary bypass surgery. The aim of this 
trial was to test the viability and safety of autologous cardiac stem cells, as well 
as determine any beneficial effects they might have. Aside from a proof of 
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concept regarding the safety of delivering autologous cardiac stem cells, the 
treatment showed a marked improvement in LVED and a decrease in infarct size 
in the time between 4mo and 12mo post-treatment within the treatment group. 
While results appear promising, the trial did not report comparisons with the 
untreated group, so direct comparison between efficacies of treatment versus 
that of a placebo cannot be concluded 28,29. 
 
Finally, the CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar 
dysfunction (CAUDECEUS) trial observed the effect of intracoronary injection of 
autologous cardiosphere derived cells (CDC) 1.5-3mo post-infarction. The 
conclusions from this proof-of-concept trial did not show any significant 
improvement in heart function, but did show a smaller scar size and increased 
myocardial thickness at 6mo and 12mo that was not seen in the control 
patients30. It is suggested that the effect of increased viable myocardial tissue in 
this instance is both through direct physical contact as well as paracrine 
stimulation to promote the regrowth of myocardium, although differentiation into 
cardiomyocytes is not a suggested mode of regeneration. 
 
All these studies taken together paint an interesting picture. Stem cell therapy 
does show a marked effect in vivo across all trials, however the effects and the 
parameters are different in each case. It is more intriguing that the type of stem 
cell does not alter the overall outcome of myocardial protection or regeneration, 
which brings up the question of what, exactly, mechanism of action is occurring 
to promote cardiac repair or survival, and if there is a means to harness and 
improve on that capability. 
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2.4.2 Mechanism of MSC therapy in cardiac repair: laboratory findings 
The field of MSC therapy for ischemic heart disease suggests three modes of 
cardiac repair: 1) differentiation of MSCs into endothelial cells and vascular 
smooth muscle cells, 2) differentiation of MSCs into cardiomyocyte cells (CMC), 
and 3) cytoprotective and regeneration effects mediated through paracrine 
release31. Initial studies utilizing stem cells to treat cardiac failure were focused 
on the hypothesis that injected stem cells would differentiate into a desired cell 
type, whether that type be cardiomyocytes, vascular smooth muscle cells, or 
endothelial cells32. The differentiation of MSCs into cardiomyocytes was one of 
the earliest and most promising findings in the field that catapulted MSC therapy 
for heart disease from a far-reaching idea to a possibly attainable goal. In this 
breakthrough study, it was observed that after 1wk under supplemented culture 
conditions in vitro, the morphology of approximately 30% of bone marrow stromal 
cells began to simulate the rod-like form of cardiomyocytes, including 
sarcomeres and centrally positioned nuclei. After 2wk in culture, the cells began 
to spontaneously beat, with synchronous beating occurring after 3wk in culture33. 
In a separate study, when implanted into fetal sheep during early gestation, 
hMSCs underwent site-specific differentiation into cardiomyocytes in addition to 
their differentiation into a variety of other cell types, proving the multipotency of 
MSCs in vivo34. The finding of cellular caridomyoplasty, or cell based cardiac 
repair, was further shown in a adult murine heart, where human MSCs were 
labeled with lacZ and injected into the left ventricle of healthy mice. Over time, 
these labeled cells began to morphologically resemble cardiomyocytes, and 
expressed cardiac specific proteins35. To test the ability of MSCs to differentiate 
at the site of injury post-MI, as opposed to in healthy myocardium, GFP labeled 
MSCs were infused into the bone marrow of irradiated mice. These mice were 
then given an MI and subsequently treated with granulocyte colony stimulating 
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factor (G-CSF) to promote the mobilization of injected MSCs into the 
bloodstream. Upon sacrifice at the 8wk time-point of the study, the ischemic 
myocardium of the mice showed evidence of GFP positive cells expressing the 
cardiac specific actinin marker, suggesting that the bone marrow MSCs not only 
homed to the site of injury, but further differentiated into CMCs in an attempt to 
aid in cardiac regeneration36. The homing of MSCs to ischemic myocardium was 
further demonstrated via intravenous systemic injection of bone marrow MSCs 
3h after coronary ligation. Transplanted MSCs differentiated into CMCs, as 
expected, but a separate population of cells expressed von Willebrand factor and 
formed vascular structures, suggesting a second form of differentiation with 
vessel-like characteristics, a finding that would help to further improve cardiac 
function following treatment after an MI37. The conclusion of these, and a number 
of other studies, is that MSCs have the ability and differentiated into CMCs and 
vascular cells both in vivo and in vitro.  
 
Despite these results, a growing body of evidence suggests that although MSCs 
have been shown to differentiate into functional cells that aid in repair, the 
percent of fused or differentiated cells is not sufficient to account for the amount 
of ventricular remodeling and vasculogenesis observed31. Rather, paracrine 
mechanisms, driven by the secretion of soluble factors from MScs, are thought to 
be the driving factor in the repair process. The strongest indications of this are in 
vitro results that indicate that the cell culture medium of MSCs alone was 
sufficient to reduce apoptosis of cells in hypoxic conditions38. Likewise, in vivo 
studies have shown a reduction in scar formation and extracellular matrix 
remodeling through the release of paracrine factors from MSCs39. Finally, and 
most interestingly, recent studies suggest that the injection of MSCs promote the 
activation of resident cardiac stem cells, stimulating cardiomyocyte replication 
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within the cardiac tissue itself, a finding that might re-open the long disputed 
concept of self-regeneration potential of the heart40-42. 
 
Although the study of the paracrine effects of MSCs on the surrounding 
myocardium is still a premature field, early experiments are beginning to lay the 
mechanistic foundation. A number of other key angiogenic, pro-survival factors 
have been attributed to MSC secretion in both normoxic and hypoxic conditions, 
including vascular endothelial growth factor (VEGF), insulin-like growth factor 
(IGF), and stromal cell-derived factor-1 (SDF-1)37,43-45.  These cytokines play a 
variety of roles in tissue remodeling, but are in general responsible for increase in 
survival and contractility of CMCs, neovascularization, and differentiation of stem 
cells (Table 2.2). Additionally, BM-MSCs under oxidative stress release 
chemoattractants including macrophage inflammatory proteins (MIP-1α, MIP-1β) 
that are associated with wound repair and inflammatory responses46. The 
expression of these proteins might help explain in vitro studies that showed 
migration of CD14+ monocytes and endothelial cells, with additional mitogenic 
effect on endothelial cells, in response to BM-MSC cultured medium. 
Furthermore, when applied to a cutaneous wound model, groups treated with 
cultured medium showed an increase in CD4/80+ macrophages and an increase 
in endothelial cell and endothelial progenitor cell recruitment, further solidifying 
the role of BM-MSC secreted paracrine factors in cell recruitment and repair43. 
 
The body of knowledge surrounding the beneficial properties of MSCs is quite 
large, and growing. As stated, the results were deemed promising enough to 
quickly implement clinical trials, which have fallen short in terms of their long-
term outcomes. The objective of future studies is to figure out a way to harness 
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the potential of MSCs to maximize their intended benefit. It is from this desire that 
the field of cardiac tissue engineering has emerged. 
 
2.5 Cardiac tissue engineering 
Simple injection of cells into the myocardium or coronary arteries have proven 
beneficial in decreasing myocardial remodeling, but their effects are diminished 
in longer-term studies, in part due to their limited cell survival at the ischemic 
area as well as their low cell retention within the myocardium47-49. The field of 
cardiac tissue engineering has developed to address this concern. There are 
currently three general categories involved in cardiac tissue engineering; 1) The 
creation of functional tissue to replace ex vivo to replace damaged myocardium, 
2) improvement on the retention of injected cells, either by encompassing them in 
an injectable hydrogel or altering the properties of the cells themselves, or 3) the 
bioengineering of a three-dimensional epicardial patch that can either act as a 
scaffold for the regenerating heart, or a vehicle to deliver therapeutics to the site 
of injury49-52.  
 
Engineered heart tissue (EHT), or the creation of an ex vivo functioning 
myocardial tissue, is arguably one of the more difficult subfields of cardiac tissue 
engineering. Strides have been made to grow engineered human myocardium on 
a 3D structure, biomimicking the human myocardium53. Groups have also been 
able to incorporate an endothelial cell vascular network within the engineered 
tissue that pairs with host myocardium when placed on healthy hearts54. The 
most promising result was an engineered heart tissue that, when placed on 
injured myocardium, showed electrical coupling to the native cardiomyocytes, 
helping to improve heart function 55. Despite this, a fully functional replacement 
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tissue has yet to be established in the clinical setting, part due to the complex 
nature of the myocardium and it’s supporting cell populations. 
 
A parallel approach within the cardiac tissue engineering field is the exploitation 
of the body’s natural mechanisms to aid in either ceasing or reversing the 
damage following an MI. One tactic is the harnessing of the paracrine effects of 
MSCs through the encapsulation of the cells within varying constructs. Of these 
constructs, two major categories of scaffolding material, synthetic and naturally 
based, have emerged.  
 
Synthetic scaffolds are appealing, in part due to the inherent control possibility 
they provide. For instance, hydrogels that are used in a variety of tissue 
engineering disciplines are chosen because their crosslinking nature provides the 
ability to utilize directed light or ionizing radiation to selectively crosslink the 
construct into a desired shape, surface morphology, and porosity56. Additionally, 
the characteristic of hydrogels to swell while maintaining their 3D structure 
provides a framework for cell survival, while its inherent porosity permits 
adequate transport of nutrients and oxygen to allow the cells to proliferate57,58. 
There are a variety of complex and simple structures that have been developed 
to help aid in cell delivery post-MI (Table 2.3). A group out of Emory recently 
“double encapsulated” MSCs, first within alginate capsules, then transplanted 
those capsules into a poly-(ethylene glycol) (PEG) patch59. Bioluminesence 
studies showed that the patch retained the cells for up to 5d at the site of 
implantation, peaking significantly at 3d with no trace of the cells by 7d. This is 
compared to the retention of simply injected cells, which showed a constant low 
level of cells, with total irradiation by 5d. When assessing cardiac function, an 
increase in both EF and SV was noted in the treatment group when compared to 
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the control group, as well as a decrease in scar size of the infarcted region and in 
increase in microvascular density in the peri-infarct region. In this study, PEG, a 
non-biodegradable polymer, was used as the delivery mechanism for MSCs, 
most-likely due to its cell retention capability after implantation. A different 
approach would be the use of a construct that is expected to degrade upon 
placement on the heart, thus releasing the cells within the construct for possible 
differentiation into cardiomyocytes and other advantageous cell types. This 
approach, when utilized on a poly(lacide-co-e-caprolactone) construct placed on 
a 10d post-MI rat model, was shown to enhance the effects of MSC therapy, 
suggesting that slow release of therapeutic cells might aid in decreasing cardiac 
remodeling, possibly due to differentiation into cardiac lineages60.  
 
The second classification of scaffolding material is one based on natural 
extracellular matrix proteins. Interest in this category of scaffolds has always 
been high due to the inherent biocompatibility of such devices. Fibrin and 
collagen have emerged as the most used foundation for regeneration, in part 
because of their biological association with wound healing. Fibrin glue has 
proven to aid in cell attachment, growth, and differentiation of cells in co-culture 
and encapsulated conditions, as well as protection of encapsulated cells from 
hypoxic environments61-63. As an added benefit, the precursors for the fibrin-
based glue, fibrinogen and thrombin, can be taken directly from the patient, 
providing a fully autologous scaffold64. Simple entrapment of bFGF into a fibrin 
glue, followed by injection into an ischemic site, improved the EF, angiogenic 
density, and regional myocardial perfusion of the injured myocardium65. Similarly, 
encapsulation of BMSCs within a fibrin glue and injection 1wk post-MI showed a 
marked improvement in cardiac function and angiogenesis61. The results of a 
simple naturally occurring biomaterial to act as a scaffold has further been shown 
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in an acellular scaffold made of Type I collagen that has been manipulated to 
mimic the physiomechanical properties of the myocardium. The simple presence 
of the scaffold was enough to preserve some of the function of the heart post-
MI66. The mechanisms of this effect are attributed to the patch’s support of the 
injured myocardium, as well as its ability to facilitate cell migration and 
angiogenesis within the patch itself. The implications of this study are two-fold; 1) 
acellular cardiac protection is a viable means of cardiac tissue engineering, and 
2) the vehicle of cellular delivery can itself help aid in cardiac regeneration if it 
properly primed to promote cell migration and angiogenesis. 
 
These are just a few of the many ongoing laboratory studies involving the 
delivery of exogenous materials to help regulate of cardiac remodeling. Of the 
studies, some provide complex multilayered structures, while others are simple 
homogenous platforms. Many incorporate therapeutic cells, but a few rely on the 
scaffold itself to provide structure for remodeling. The framework of patches 
varies from proteins naturally found in the body, to engineered polymers. All have 
shown promise in their ability to diminish detrimental effects of MIs, however, the 
difficulty relies on the ability of such therapeutics to be translated into the clinical 
setting. The administration of the patch must be able to be done using minimally 
invasive techniques, preferably via laparoscopic surgery or coronary delivery, to 
ensure that collateral damage to the patient does not occur as a result of 
treatment. If this can be established, cardiac tissue engineering might prove 
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2.6 Animal MI Models 
Animal models play an imperative role in understanding the progression and 
treatment of CVD. There are currently a number of models for a wide range of 
CVDs, covering a variety of animals, from mice, to rabbits, to dogs, to pigs67. 
Each model presents with its own unique characteristics as well as downfalls. 
The largest (porcine) and smallest (murine) models are discussed here. 
 
Pigs are considered as an excellent animal model to explore human diseases 
and recapitulate clinical phenotypes due to their relative size, similar 
physiological characteristics, and comparable morphological anatomy to that of 
humans68. The size of the pig allows occlusion of the LAD to be performed via 
cardiac catheterization, where the coronary arteries are approached via the 
femoral artery and obstructed using an angioplasty technique69,70. This 
obliterates the need to perform open-heart surgery and decreases the possibility 
of additional ventricular remodeling that may be associated with such an invasive 
technique. Additionally, the coronary anatomy and organ structures are 
analogous to those of humans, decreasing the inevitable variably in action that is 
so often seen in translational medicine71. Despite the advantages of a porcine 
model, the procedure is difficult to master, requiring full 24-hour veterinary staff 
supervision for both the surgical method as well as follow up monitoring. Due to 
this, and the overall cost of the porcine model, the use of pigs is best saved for 
later studies after therapeutics have proven themselves in smaller animal 
models. 
 
One of the most relied upon small animal models for almost every diseased state 
is the mouse, thanks in part to the ease of genetic manipulation of the murine 
species. Recently, the mouse has emerged as a tool for studying cardiac 
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remodeling post-MI and provides a platform to test possible intervention 
strategies for CVD32,67,72. The mice are small and easy to maneuver, with a full 
MI procedure lasting under 45m, allowing for a relatively large sample size 
without the restraints associated with larger animal models. However, just as with 
any other model, there are potential downfalls for the use of a smaller animal 
models. Specifically, the cardiovascular structure and coronary artery distribution 
is vastly different in the mouse compared to the human. The left coronary artery 
in the mouse does not divide into a left circumflex and left anterior descending 
artery, as in humans. Instead, the left coronary artery courses along the left 
ventricular free wall, and has a variable branching pattern as it descends along 
the free wall73. As such, to emulate the occlusion of the LAD that is characteristic 
of an MI in humans, one must instead occlude the entire left coronary artery in 
mice, beginning immediately after it emerges past the tip of the left atrium. With 
this approach, a positive infarction can be identified as being accompanied by left 
ventricular dilation, a decrease in systolic function, and an increase in filling 
pressure74-76. These can be qualitatively measured on their own, and can also be 
used in overall calculations of heart function, including a decrease in ejection 
fraction and stroke volume, an increase in the ventricular diameter, and a 
decrease in ventricular heart wall thickness, as determined by echocardiography 
and histological staining77-80. 
 
2.7 Conclusion and project overview 
Current medical intervention post-myocardial infarction focuses on maintaining 
the remaining healthy heart tissue rather than preventing or reversing damage to 
the infarcted tissue. The overall goal of this project is to harness the therapeutic 
properties of stem cells through encapsulation in an engineered hydrogel in order 
to prevent tissue damage following a heart attack, and to test the efficacy of the 
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treatment using a murine MI model. This preventative measure will save the 
heart tissue from being replaced by non- contractile scar tissue, preserve heart 
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2.9. Tables 
Time Morphological Changes 
0-1.5h Reversible injury 
3h MI can be identified via enzymatic staining 
4-12h Begin coagulation necrosis 
12-24h Gross features of MI begin to become apparent. Dark mottling in 
ischemic region. Beginning of neutrophil infiltration. 
1-3d Acute inflammation most apparent.  
3-10d Wave of macrophages responsible for removal of dead myocytes 
10-14d Early granular tissue formation 
2w-8w Collagen deposition 
8w - ∞ Dense collagenous Scar 
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Stem-Cell Secreted Paracrine Factors Mechanism of Action 
VEGF, HGF, IGF-1, SDF-1, bFGF, TGF-β, PTX-3, TSP-1 Survival 
VEGF, bFGF, FGF2, HGF Contractility 
VEGF, IGF-1, SDF-1, PDGF-AA, TGF-β, TNF-α, IL-1, IL-8, Ang-1,  
Ang-2, MCP-1 Neovascularization 
VEGF, IGF-1, HGF, TNF-α Differentiation 
IL-10, MMP-2, MMP-9, MCP-1, TGF-β, TIMP-1, TIMP-2, TIMP-9, HGF, 
IL-1, Activin A Remodeling 
MIP-1, MIP-2, MMP-9 Chemotaxis 
Table 2.2: Secretion factors and their role in remodeling and chemotaxis. 
Adapted from Mirotsou et al. 
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Table 2.3: Overview of cardiac patch in vivo experiments and results. (+) 
designates a positive result, (-) designates a negative result, (*) designates that 
the parameter was not tested, and (/) designates a parameter that is not 
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3. A HYDROGEL CONSTRUCT AND FIBRIN-BASED GLUE APPROACH TO 




The murine MI model is widely recognized in the field of cardiovascular disease, 
and has consistently been used as a first step to test the efficacy of treatments in 
vivo1. The traditional, established protocol has been further fine-tuned to 
minimize the damage to the animal. Notably, the pectoral muscle layers are 
teased away rather than simply cut, and the thoracotomy is approached 
intercostally as opposed to breaking the ribs, preserving the integrity of the 
ribcage. With these changes, the overall survival rate for mice receiving an MI is 
near 70%.  
 
Stem cell therapies aimed to alleviate the damage caused by MIs have shown 
promise over the years for their pro-angiogenic and anti-apoptotic benefits. 
Current approaches of delivering cells to the heart surface typically involve the 
injection of the cells either near the damaged site, within a coronary artery, or 
into the peripheral blood stream2-4. While the cells have proven to home to the 
damaged myocardium, functionality is limited by their poor engraftment at the site 
of injury, resulting in diffusion into the blood stream5. This obstacle can be 
overcome with the use of a cell-encapsulated hydrogel patch. The patch is 
fabricated prior to the surgical procedure and is placed on the injured 
myocardium immediately following the occlusion of the left coronary artery. To 
adhere the patch in place, a biocompatible external fibrin glue is placed directly 
on top of the patch, allowing for it to dry to both the patch and the heart surface. 
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This approach provides a novel adhesion method for the application of a delicate 
cell-encapsulating therapeutic construct. 
 
3.2 Introduction 
A myocardial infarction (MI) is defined as the interruption of blood to a region of 
the heart caused by the occlusion of a major coronary artery. The damage 
resulting from an MI is due to the remodeling of the viable heart tissue into non-
functional scar tissue, which decreases the ability of the heart or, more 
specifically, the left ventricle, to beat properly. This results in a decrease in the 
volume of blood that can be delivered to the body with every heartbeat, known as 
the stroke volume, and the percentage of blood that is pumped out of the heart 
with each heartbeat, known as the ejection fraction6. These, along with other 
diminished functions, increases the strain on the rest of the heart to maintain 
adequate function. Often, this increased strain can become so severe that it 
causes a second heart attack, a phenomenon seen in approximately 10% of 
individuals7. 
 
While medical practices have evolved to treat the immediate aftermath of an MI, 
no technique has been developed to halt, slow, or reverse the negative side 
effects of tissue remodeling. Stem cell therapies have emerged as a possible 
avenue for such a treatment, however, despite their promising potential, stem 
cells have not proven successful in the clinical setting. One theory for their 
shortcomings is the inability to ensure the beneficial cells remain at the site of 
infarction long enough to generate favorable results5. It has been shown that no 
more than 24% of cells that are simply injected into the site of infarction survived 
and remained at the damaged site 1d post-delivery2. A possible prospect to 
addressing this issue of cell retention is to develop biocompatible hydrogel 
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systems that encapsulates cells and can be delivered to the damaged site. This 
approach would ensure cell-to-tissue contact over an extended period of time, 
increasing the length of time the cells can provide beneficial factors to the 
underlying myocardium. 
 
A bottleneck to the patch approach is the difficulty of adhering the patch to the 
heart surface. Many groups have overcome this through a variety of techniques, 
the most prevalent being a simple suture to tie the construct to the heart 
surface8,9. This has proven successful in a number of cases in which the 
construct is made of a stiffer material, but fails when attempted on a hydrogel 
system, due to the high water concentration and delicate nature of the patch 
construct. To overcome this we have developed a fibrin glue external adhesive 
system that mimics the chemistry of clot formation. Fibrin glue has been used in 
numerous medical surgeries, including dura tears, bronchial fistulas, and corneal 
transplantation, highlighting the biocompatibility of the product as a wound 
sealant10-12. Additionally, fibrin has been used in a variety of cardiac purposes, 
including surgical treatment of left ventricular ruptures and coronary artery 
bypass surgeries, however, its use as an adhesion glue for a cardiac patch is not 
commonly used 13-16. A simple formulation of thrombin and fibrinogen results in a 
biocompatible glue that can be placed directly on the outside of an external 
cardiac patch, providing a viable adhesion system to ensure patch to heart 
interaction. 
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3.3 Materials and Methods 
3.3.1 Instrument Preparation 
All non-disposable instruments used are autoclaved prior to the surgical 
procedure to ensure sterility. Instruments used multiple times in a session are 
sterilized with a glass bead sterilizer between uses. 
 
3.3.2 Cell Preparation 
Stem cells are thawed at least 24h prior to creation of the hydrogel construct. 
Approximately 5x106 cells are resuspended in 30mL of TheraPeak MSCGM-CD 
(Lonza) supplemented with 5% FBS and split into two T-75cm2 flasks. The cells 
were incubated at 37oC and 5 %CO2 until ready for use. 
 
3.3.3 Hydrogel Preparation 
Patches are prepared 1d prior to the surgical procedure using a 
stereolithography apparatus (explained in detail in chapter4). In short, cells are 
resuspended in a pre-polymer solution of 20% Poly(ethylene-glycol)1000 
dimethacrylate (Polysciences Inc). After creation, hydrogels are incubated 
overnight in cell culture medium to allow for cells to adjust to the environment 
within the patch. Patches are used within 24h of fabrication and transferred to the 
heart surface within 10m of removal from the incubator. 
 
3.3.4 Fibrin-based glue 
Fibrinogen (Sigma-Aldrich) and Thrombin (Sigma-Aldrich) were reconstituted into 
a 100mg/mL and 40mg/mL stock solution, respectively. Both solutions were kept 
on ice until mixing, at which time a 4:1 fibrinogen to thrombin solution was made. 
The formulation was mixed via gentile pipetting until desired viscosity was 
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reached, at which time it was transferred to the surface of the heart using a 10µl 
pipette. 
 
3.3.5 Echocardiography  
Echocardiography is described in detail in Chapter 4. In brief, animals are placed 
under anesthetics by isoflurane inhalation and 2D M-mode echocardiographic 
traces are collected by the Ultrasound-Visual Sonics Vevo 2100.  
 
3.3.6 Histological staining 
Histological staining techniques are described in detail in Chapter 4. In brief, At 
the time of euthanasia, the hearts are collected from the animals and placed in a 
10% formalin solution for 24h, after which time the hearts are transferred to 70% 
ethanol and kept at 4oC until tissue processing. Hearts are processed, 
embedded, sectioned, and stained with both a Hematoxylin and eosin (H&E) and 
Masson’s Trichrome stain. 
 
3.4 Procedure 
3.4.1 Surgical preparation 
The final outcome of the surgical technique described below is the full occlusion 
of the left coronary artery of the mouse, the transfer of a hydrogel patch to the 
site of infarction, and the administration of a fibrin based glue to ensure patch 
adhesion at the desired site. Procedure is in full compatibility with IACUC 
protocol number 13302 and has been approved by the division of animal 
resources. 
 
Each mouse is evaluated prior to the procedure to assure that the animal is in 
good health. Animals are placed into an anesthetic chamber and exposed to 5% 
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isoflurane with a 1 L/min O2 support. The level of anesthesia is monitored by toe 
pinch reflex. Once the animal is properly anesthetized, they are weighed and 
placed on the intubation stand. A light source is directed towards the animal’s 
chest cavity and forceps are used to retract the laryngeal surface and expose the 
vocal cords. A 20G angiocath is carefully guided between the vocal cords, and 
smoothly inserted into the trachea. Proper insertion is detected by a mechanical 
movement of the chest cavity once the catheter is connected to the small animal 
ventilator. Ventilation settings are adjusted to the weight of the animal based on 
the manufacturers guidelines. Once intubated, the animal is placed in the supine 
position on a heating pad to prevent hypothermia. Hair is removed from the 
surgical site through the use of a depilatory cream and the site is sterilized by 3 
alternating scrubs of betadine and ethanol. A drape is placed to expose just the 
surgical site, and vet ointment is placed on the eyes to prevent dryness during 
the procedure. 
 
3.4.2 Thoracotomy and MI induction 
The thoracotomy is performed on the left side of the animal, therefore, a skin 
incision is made approximately 1 cm to the left of the sternum, and runs the 
length of the sternum. Forceps are used to separate the muscle layer from the 
underlying ribcage in two steps. A delineating line is observed that represents the 
pectoralis major muscles of the animal. This muscle is slightly lifted and 
separated from the underlying external oblique muscle and retracted medially. 
The external oblique muscle is then freed from the underlying ribcage in the 
same manner, and retracted laterally, providing an unobscured view of the 
second, third, and fourth ribs (Figure 3.1a). The thoracotomy is performed 
between the third and fourth ribs. The fourth rib is gently lifted, and a cauterizer is 
used to open the chest cavity. Retractors are placed to further expose the cavity 
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and access the heart (Figure 3.1b). Forceps are used to rupture the thin 
pericardium of the heart. The left coronary artery is ligated with an 8-0 
monofilament nylon suture. The suture is placed approximately 4mm from the 
apex of the heart, directly below the bottom tip of the left atrium. Proper suture 
placement can be determined by a blanching of the ventricular myocardium and 
an increase in the size of the left atrium after the suture has been tied. 
 
3.4.3 Patch placement 
Patches are kept at 37 oC and 5% CO2 conditions until use. The patch is gently 
lifted using a flat-ended spatula and gently placed on the surface of the heart. To 
prevent slipping off the left ventricle, the patch can be held in place by lightly 
maintaining contact using either the spatula or the tip of a pair of forceps. The 
glue is prepared and mixed by repeated pipetting until it begins to thicken, 
usually within 1m after the beginning of the preparation. Once the solution 
viscosity reaches the desired level, approximately 10µL is quickly transferred to 
the patch surface. The clotting time of the fibrin glue is rapid, providing a small 
window of opportunity for efficient transfer of the glue. The chest cavity is left 
open for approximately 1-2m following the addition of the glue to allow for full 
crosslinking and minimize movement of the patch from the heart surface. 
 
3.4.4 Closure 
All closing sutures are done using a 6-0 monofilament nylon suture. The rib layer 
is closed with three to four individual interrupted sutures (Figure 3.1c). Before full 
closure of the intercostal layer, a PE-10 cannula is inserted into the incision to 
evacuate the chest cavity after closure is complete and reestablish proper 
intrapleural pressure (Figure 3.1d). The pectoral muscles are closed with three to 
four individual interrupted sutures and the skin layer is sealed with a continuous 
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suture (Figure 3.1 e,f). Following full closure, a 1.0mL syringe is attached to the 
end of the cannula and used to evacuate the chest cavity. A tissue adhesive is 
applied to the incision site to reinforce the suture site. 
 
3.4.5 Post-surgical Treatment 
Mice are given an injection of buprenorphine (0.05-1.0 mg/kg) and carprofen (2.2 
mg/kg) subcutaneously immediately following the coronary ligation procedure 
and wound closure, but at least 20m prior to revival. Both drugs are administered 
6-8h after surgery, and then given twice daily for up to 3d to control pain and 
distress. The animals are monitored continuously until conscious and every hour 
for the first 4h following surgery. A second checkup the night of the surgery 
occurs 2-4h later to administer a second dose of analgesic.  Animals are 
monitored daily after the second day following the procedure, until animals 
appear stable.  
 
3.4.6 Analysis of heart function and histology 
Echocardiographs are performed on the mice 4wk following the procedure to 
determine the extent of damage following the MI. Mice are anesthetized with 4-
5% isoflurane within an anesthesia chamber for induction of inhalation 
anesthesia, and then 2% isoflurane via face mask for maintenance anesthesia. 
Echocardiographic traces are collected and later analyzed for cardiac function 
assessment. Upon the termination of the experiment, animals are sacrificed and 
their hearts are collected for histological analysis. H&E stains are performed to 
assess overall heart morphology and cell population, while the Masson’s 
Trichrome stain can determine any fibrosis and collagen deposition that might 
have occurred due to ventricular remodeling.  
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3.5 Results 
During the surgical procedure, ligation of the left coronary artery can be identified 
by a marked blanching downstream of the occluded artery. As a test before tying 
the knot, the suture can be tightened briefly to check if it is in the appropriate 
place. Additionally, since occlusion of the artery results in almost instantaneous 
decrease in the ability of the left atrium to properly beat, the left atrium will 
enlarge in response to a backflow of blood in the system. 
 
M-mode echocardiography measurements taken as early as 2d post-infarction 
show a cessation of left wall movement, indicative of the muscle reconstruction 
(Figure 3.2 a,b). Qualitative calculations made from the data show a decrease in 
ejection fraction and stroke volume in the infarcted hearts. At the termination of 
the experiment, when the hearts are collected for histological purposes, a clear 
dilation of the left ventricle can be seen, along with a thinning of the left 
ventricular wall, and the deposition of collagen that denotes scar tissue 
deposition in place of functioning cardiomyocytes (Figure 3.2 c,d). 
 
Care is taken in the transfer of the patch so as to ensure its location on the left 
ventricle (Figure 3.3 a). Administration of the glue aids in maintaining the patch 
location after chest closure. For our purposes, the adhesive system must be 
viscous enough to allow precise placement control and minimize subsequent 
runoff into surrounding organs, but malleable enough not to interfere with heart 
function. Preliminary tests were performed to calculate the viscosity, gelation 
time, and stiffness of various fibrinogen/thrombin ratios, in order to determine the 
proper combination that suits our needs. In vivo analysis was performed to test 
the ability of the fibrin glue to maintain patch-to-tissue adhesion while still 
allowing for full heart function (data not shown). Upon histological analysis, the 
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presence of the hydrogel construct can be seen thanks to the administration of 
the fibrin gel (Figure 3.3 b). It should be noted that the fibrin glue did not harm the 
myocardium, as evidenced by the lack of tissue remodeling or ventricular 
thinning at the site. The cardiomyocytes remain in tact despite the addition of 
both a cardiac patch and its accompanying glue. Additionally, viability testing 
confirmed that that the administration of fibrin glue to the external surface of a 




With this approach to the murine MI model, we have developed a system that 
minimizes the damage to non-myocardium areas that are associated with other 
murine MI techniques. These areas include damage caused by a tracheostomy, 
the cutting of the muscular layer, and the breakage of ribs to expose the chest 
cavity. These changes have resulted in a 70% survival rate. We believe this 
improvement is due to the care taken to keep as much of the major structures, 
including the ribs and muscle layers, in tact during the surgical procedure.  
 
Fibrin glue is known in both the laboratory and clinical settings thanks to its ability 
to quickly aid in clot formation, as well as its potential to deliver and host MSCs17. 
For our purposes, fibrin glue served as a biocompatible approach to adhering a 
water-based hydrogel construct to the surface of the heart. The use of a fibrin-
based glue has proven successful in keeping the hydrogel construct at the 
damaged site for up to 8wk, with the possibility for tissue contact of a longer 
period of time. The use of this adhesion system allowed control for placement of 
the delicate construct without the need for additional sutures that harm the 
myocardium as well as the construct itself. We have found that the glue itself is 
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non-toxic to the encapsulated cells and does not negatively affect the underlying 
tissue. 
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3.8 Figures 
 
Figure 3.1: Murine thoracotomy and subsequent chest closure. After the 
initial skin incision, two muscle layers are teased back to expose the 2nd, 3rd, and 
4th ribs (a). The thoracotomy is performed between the 3rd and 4th ribs using a 
cauterizer, and the ribs are retracted to gain better access the heart (b). After the 
MI procedure and patch placement, the rib layers are sutured closed with 2-3 
interrupted sutures (c). Prior to the final suture placement, a PE-10 cannula is 
inserted between the 2nd and 3rd ribs (d). The muscle layers are then sutured (e) 
followed by the suturing of the skin (f). 
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Figure 3.2: Left coronary artery ligation results in a decrease in cardiac 
function as measured by echocardiography. M-mode echocardiography of 
healthy (a) and infarcted (b) hearts. Infarcted hearts show a clear lack of wall 
movement where viable tissue has been replaced with scar tissue. This 
correlates with a measureable decrease in left ventricular ejection fraction and 
overall cardiac stroke volume. Histological analysis of healthy (c) and infarcted 
(d) hearts shows dilation of the left ventricle and thinning of the left ventricular 
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Figure 3.3: Application of fibrin glue ensures patch adhesion to the heart. 
The patch is placed on the surface of the heart while the chest cavity is exposed 
during the procedure (a). Once placed, a fibrin-based glue is added on top of the 
heart and allowed to dry. The patch can clearly be seen on histological sections 
of heart tissue that were collected at 1wk post-procedure (b). Results are 
consistent for up to 8wk of adhesion. 
 
  
	   48	  
 
 
Figure 3.4: Fibrin-based glue does not harm encapsulated tissues. Cell 
viability was measured via MTT analysis 1wk after the administration of a fibrin-
based glue. The viability of cells within the patch was not affected by the addition 
of the glue to the surface of the construct. 
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4. INCORPORATION OF MICROCHANNEL STRUCTURES IN 
MESENCHYMAL STEM CELL ENCAPSULATED HYDROGELS IMPROVES 




The major injury attributed to myocardial infarctions is due to the vast remodeling 
that occurs in the hypoxic environment post-occlusion of the coronary vessel. 
Over the past several years there has been an increasing interest in the use of 
mesenchymal stem cells (MSCs) to help cease or reverse the myocardial fate of 
collagen deposition and scar tissue formation, and help aid in the recovery of 
patients that suffer from debilitating heart attacks. In this study, we employ a 
poly(ethylene-glycol) dimethacrylate (PEGDMA) hydrogel construct to 
encapsulate MSCs and deliver them to the epicardial surface with the aim of 
concentrating their therapeutic benefits at the site of injury. A stereolithographic 
apparatus (SLA) was used to provide user control of the hydrogel fabrication and 
design parameters resulting in the incorporation of microchannels within the 
patch, creating multiple reservoirs in which soluble factors secreted from the 
MSC’s can concentrate and maximize their efficacy. Incorporation of the 500µm 
channels both increase vascular density and direct vascularization. Two cell 
concentrations were used to test the effect of cell number on angiogenesis in ovo 
and cardiac function in vivo. Placement of a cell encapsulated patch directly 
following the occlusion of the left coronary artery in a murine model showed 
significant improvement in the ejection fraction, fractional shortening, and stroke 
volume. Most importantly, the overall number of therapeutic cells required to 
display such a result were drastically lower than previous studies would suggest, 
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with significant improvement seen with as little as 1,400 MSCs/construct. This 
study demonstrates the ability to control the hydrogel construct to maximize its 
potential benefits in vivo in addition to suggesting that therapeutic effects of 
MSCs post-MI can still be obtained with a drastic decrease in the overall number 
of cells delivered to the myocardium. 
 
4.2 Introduction 
Despite medical progress in treatment and intervention, cardiovascular disease is 
still a leading cause of morbidity and mortality for both men and women 
worldwide. The immediate goal of current post-myocardial infarction (MI) 
treatments is to open the blocked coronary arteries and return blood flow to the 
injured cardiac muscle, with the hope that early recovery of blood flow will 
decrease permanent damage caused by the hypoxic insult1-3. This approach is 
centered on supporting the remaining tissue, however, it does not actively 
prevent or reverse the degradation of the myocardium at the ischemic site4. In 
fact, an expected outcome of reperfusion therapy is collateral damage of injured 
tissue from reactive oxygen species that arise with a sudden influx of oxygenated 
blood to a previously hypoxic region5-7. Recently efforts are increasingly made to 
harness the regenerative capabilities of mesenchymal stem cells (MSC) and 
using them to treat congestive heart failure through a number of mechanisms, 
including their secretion of pro-angiogenic and anti-apoptotic cytokines8-11. 
Additionally, MSCs are a particularly promising cell type due to their relative ease 
of isolation and expansion from either bone or adipose tissue, as well as their 
immunoprivileged profile that allows them to be delivered to a host animal with 
little to no inflammatory response12.  
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There are three means currently being employed to deliver MSCs to infarcted 
tissue: 1) direct intramyocardial injection to the injured site; 2) systemic 
intravenous infusion, in which a fraction of transplanted cells have been shown to 
home to the injured tissue; and 3) local intracoronary delivery via a catheter 
placed within the coronary vessels. All three of these means have demonstrated 
a decrease in infarct size, less severe ventricular remodeling, and improved 
vascularization11,13-15. While these reports are encouraging, it has been reported 
that 7d after transplantation, stem cell concentration at the site of injection 
decreases by 10-fold, with no trace of stem cells after 3wks, suggesting massive 
cell loss away from the injured tissue14,16. This restricts the efficacy of stem cell 
therapy for ischemic heart disease and limits the full potential of MSCs, and 
might help explain the limited efficacy of such therapies when applied to the 
clinical setting17-21. 
One proposed solution to this challenge is the use of a cell-loading patch as a 
vehicle to deliver the cells directly to the heart surface, ensuring that the MSCs 
remain in close proximity to the injured tissue. There are a variety of approaches 
to a cell-loaded patch for the purposes of tissue engineering and myocardial 
regeneration	  22-26. Many of these show increased retention of the cells at the site 
of injury, as well as neovascularization and differentiation of implanted cells into 
cardiomyocytes. What is less characterized in these studies is the role, if any, 
secreted cytokines play in the regeneration capability of implanted cell-loaded 
patches. Implanted patches should be rigid enough to maintain its structural 
integrity against repeated cardiac contraction; however, a rigid matrix typically 
presents limited permeability, resulting in the loaded cells to lose their viability 
and, consequently, their secretion activities. We have focused not only on the 
ability of maintaining cell viability within the patch, but the constitutive secretion of 
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cytokines from the patch into the surrounding environment. With this approach, 
the MSCs loaded in the patch should be able to sustainably secret cytoprotective 
factors, such as thrombospondin-1 (TSP-1), and angiogenic factors such as 
vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8)25,27-34. The 
resulting angiogenesis within the ischemic tissue would keep the tissue viable 
long enough for the vasculature to regenerate and sustain myocardial function. 
To resolve these challenges, in this study, we hypothesized that loading stem 
cells into a hydrogel implant we previously designed to be stiff and permeable 
would support cellular viability and secretion activities.  Therefore, the resulting 
stem cell-loading hydrogel patch would be useful to promote vascularization and 
subsequently retain cardiac function of heart damaged by tissue ischemia.  To 
examine this hypothesis, we loaded bone marrow derived mesenchymal stem 
cells (BMSCs) into a hydrogel formed from cross-linking of poly(ethylene glycol) 
dimethacrylate (PEGDMA). The cell-loading hydrogel was fabricated using a 
stereolithographic assembly (SLA) unit35. Additionally, microchannels that can 
serve as a drainage of cell-secreting soluble factors to tissue, and in turn 
increase the angiogenic potential of the gel patch, were added to the construct 
structure36. The cytokine secretion profile of the cells within the patch was 
explored and the angiogenic capability was determined. Altogether, we believe 
that this hydrogel patch would greatly serve to improve quality of cell therapies of 
various cardiovascular diseases due to its constitutive secretion of paracrine 
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4.3 Materials and Methods 
4.3.1 Cell preparation 
VEGF secreting BM-MSCs (Lonza, Basel, Switzerland) were cultured in 
TheraPEAK MSCGM-CD mesenchymal stem cell medium (Lonza) supplemented 
with 5% fetal bovine serum (FBS), 100 U mL-1 penicillin, and 100 mg mL-1 
streptomycin (Gibco, Carlsbad, CA, USA). Cells were incubated at 37oC and 5% 
O2 in 175 cm2 flasks to 80% confluence. When preparing for fabrication, cells 
were lifted with 0.25% trypsin and 0.04% EDTA in HBSS (Gibco, Carlsbad, CA, 
USA) and gently added to the pre-polymer solution. 
4.3.2 Hydrogel fabrication 
The hydrogel fabrication method was described in detail in a previous 
publication17. In brief, Poly(ethylene glycol) dimethacrylate (PEGDMA) of 1000 
mol wt. (Sigma Aldrich, St. Louis, MO, USA) was dissolved in sterile 1x PBS to 
obtain a 20% w/v solution pre-polymer solution. The photoinitiator, 1-[4-(2-
hydroxy- ethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one (Irgacure 2959, 
Ciba, Tarrytown, NY, USA), was dissolved in DMSO and added to the pre-
polymer solution for a final w/v of 0.5%. Depending on the desired condition, 
medium either with or without cells was mixed with the pre-polymer solution 
immediately before fabrication, resulting in a 20% concentration of cells/medium. 
The final pre-polymer solution consisted of 20% PEGDMA, 0.5% photoinitiator, 
and 20% cells/media. A stereolithography apparatus (SLA, Model 250/50, 3D 
Systems, Rock Hill, SC, USA) was used to fabricate the hydrogel constructs. 
Computer aided design models were generated using AutoCAD 2009 (Autodesk, 
San Rafael, CA, USA) and exported to stereolithography (STL) format. The SLA 
software, 3D Lightyear v1.4 (3D Systems, Rock Hill, SC, USA), was used to slice 
the 3D models into a series of 2D layers from a user-specified thickness. Once 
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the fabrication procedure was finished, the hydrogels were rinsed multiple times 
with 2mL of culture media at each rinse to remove uncrosslinked polymer. 
4.3.3 Viability tests 
Each prepared hydrogel patch was transferred to a well of a 96-well plate and 
incubated in 200µL of media until viability testing was performed. Two forms of 
viability testing were done; a live/dead viability/cytotoxicity test (Life 
Technologies, Carlsbad, CA, USA) and an MTT assay. For the live/dead assay, a 
working solution consisting of 1µL of calcein AM and 2µL of Ethidium 
homodimer-1 added to 1mL of sterile 1x PBS was prepared immediately prior to 
performing the assay. The media was removed from each construct-containing 
well and 150µL of the working solution was added. After 20min, the patches were 
visualized under fluorescent microscopy. For quantitative analysis, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to the 
media of the hydrogels at a ratio of 1:5 volume of MTT to volume of media and 
the patches were incubated for 4h. After the incubation period, absorbance was 
measured at 490 nm using a plate reader. 
  
4.3.4 Secretion factor assessment 
The supernatant was collected from cell cultures and measured for production of 
a variety of cytokines using a human angiogenesis antibody array kit (R&D 
systems, Minneapolis, MN, USA). The assay was run following the manufactures 
protocols. VEGF secretion was quantified using a VEGF human ELISA kit (Life 
Technologies, Carlsbad, CA, USA). Media was collected from cell encapsulating 
hydrogel constructs at days 1, 3, 5, and 7, and stored in -20oC prior to running 
the assay. 
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4.3.5 Chicken chorioallantoic membrane (CAM) assay 
The ability of the patch to induce neovascularization was examined by implanting 
the cell-encapsulated patch onto a chicken chorioallantoic membrane (CAM) of a 
1wk old chick embryo. Fertilized chicken eggs (Hy-Line W-36) were obtained 
from the University of Illinois Poultry Farm (Urbana, IL). The CAM was exposed 
by perforating a region of the egg shell and the construct was placed directly on 
the uncovered CAM. The perforated region of the shell was then sealed and the 
embryos were reincubated at 37oC and 5% O2. The CAM was observed at 
varying time-points throughout the incubation period to ensure survival of the 
embryo. At the termination of the experiment, the embryos were exposed to 4% 
formalin solution to fix the structures, and the constructs and were located and 
excised from the remainder of the membrane. These constructs and their 
accompanying CAM were imaged and incubated for 24h in a 4% formalin 
solution, after which time they were processed, embedded, and sliced for 
histological analysis. Sections were stained with α-smooth muscle actin to 
highlight vessel structures. Digital images of the stained sections were collected 
with a NanoZoomer Slider Scanner/Digital Pathology System (Hamamatsu, 
Hamamatsu, SZK). 
 
4.3.6 Myocardial Infarction (MI) model 
Prior to surgery, mice were anesthetized in an anesthetic chamber with 5% 
isoflurane accompanied by and 1 L/min supportive O2 flow. Their weight was 
recorded and mice were intubated with a 20G angiocath tube and connected to a 
small animal ventilator (160bpm), where 1.5% isoflurane  and 1 L/min O2 flow 
was administered. The mice were placed on a heating pad in the supine position. 
Hair was removed from the chest surgical site and an inch long vertical incision 
was made slightly to the left of center. Two muscle layers were teased back and 
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sutured in the retracted position. An intercostal incision was made between the 
third and fourth ribs and the heart was exposed. A single 8-0 monofilament 
suture (Johnson & Johnson, NJ) was placed to ligate the left coronary artery and 
occlude blood flow to the apex of the heart. Using a 6-0 monofilament suture 
(Johnson & Johnson, NJ), the ribs and muscle layers were closed by interrupted 
suture and the skin layer incision was closed by a continuous suture. The 
isoflurane administration was ceased before the removal of the tracheal tube 
from the mouse, and animals were monitored until full recovery. Four conditions 
of MI’s were tested: no patch placement (n=3), patch without cells (n=3), patch 
with 0.4x106cells/mL cell concentration (n=3), patch with 2.0x106cells/mL cell 
concentration (n=4). Additionally, control animals in which no surgical procedure 
was performed were used as negative controls (n=27). 
 
4.3.7 Echocardiography 
A VisualSonics Vevo 2100 (VisualSonics, Toronto, Canada) small animal 
ultrasound was used to perform echocardiography on the mice at 4wks post-
operation. Animals were placed in an anesthetic chamber and 5% isoflurane was 
administered with 2 L/min of supportive O2. Once properly anesthetized, the 
animals were moved to a nose cone and the percent of isoflurane was decreased 
to 1.5-2%. The imaging area was cleared using a depilatory cream and 2D M-
mode echocardiography was performed on the animals. All heart function 
calculations were made using the Vevo 2100 software. 
 
4.3.8 Histological analysis of heart sections 
Animals were sacrificed at 4 and 8 wk post-surgery and their hearts were 
collected, fixed in a 10% formalin solution, and embedded in paraffin. Tissue was 
sliced and cross-sections were stained for Hematoxylin and Eosin and Masson 
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Thrichrome Blue. Digital images of the stained sections were collected with a 




4.4.1 Cell encapsulated hydrogel  
The hydrogel was constructed from a poly(ethylene glycol) dimethacrylate 
(PEGDMA) polymer using a stereolithography apparatus (SLA). The SLA 
approach focuses a UV light directly on the polymer solution, allowing for 
controlled crosslinking at the site of light focus (Figure 4.1). This technology 
provides a platform for layer-by-layer fabrication of a cell-encapsulating hydrogel 
via in situ polymerization. The precision of the photocrosslinking allows for 
detailed control of the three-dimensional features of the construct, providing a 
mechanism to incorporate patterns within the patch.  
 
With this control, we incorporated 9 separate microchannels that span the 
thickness of the patch, with two separate conditions of diameters 500µm and 
1000µm alongside a patch with no additional features (Figure 4.2). By 
incorporating BM-MSCs within the pre-polymer solution, we were able to entrap 
the cells in a uniform distribution throughout the construct (Figure 4.2). The 
concentration of cell incorporation varied between no cells (herein referred to as 
blank), 0.4x106 cells/mL (low concentration), and 2.0x106 cells/mL (high 
concentration). Overall, through the variation of microchannel diameter and cell 
number, there were 9 conditions tested throughout the experimental procedures, 
each with differing surface to volume ratios and total cell numbers (Table 4.1). 
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4.4.2 Cell Survival and Cytokine Secretion 
Long-term cell viability within the constructs was analyzed by two methods. An 
MTT assay was used for quantitative analysis of cell survival, and a live/dead 
assay was used to visualize and relate the ratio of live cells to apoptotic cells. 
Constructs of 500µm diameter and high cell concentration were cultured for up to 
7d and cell viability was tested at days 1, 3, 5, and 7 of culture using the MTT 
assay. There was no decrease in cell viability within the patch for up to 3d post-
encapsulation, at which time the viability within the patch began to decrease, with 
an overall survival of 60% at day 7 post-fabrication (Figure 4.3). To obtain a 
broader picture of the cell population and its changes over time, a qualitative 
live/dead cell viability stain was performed at days 1, 7, and 14. There appears to 
be a relative abundance of dead cells at day 1, with a relatively even ratio of 
dead cells to live cells, however, the number of dead cells does not seem to 
increase with time, as the MTT analysis would suggest (Figure 4.4). Instead, we 
see leakage of cells out of the patch, which can be identified in the live cell 
images by their morphological change that is characteristic of plastic adherence 
of MSCs. Thus, the decrease in cell numbers can be attributed to a gradual cell 
escape from the construct instead of merely cell death within the patch. 
 
Next, the secretion factor profile of the encapsulated cells were examined to 
determine their role in cardiac remodeling and angiogenesis. The permeability of 
the PEGDMA hydrogel allows for the release of cytokine secretion from the 
construct into the culture media. Testing the culture media on a cytokine array, 
we found that BM-MSCs encapsulated within the construct secreted a variety of 
pro-angiogenic factors, including interleukin-8 (IL-8), Pentraxin-3, vascular 
endothelial growth factor (VEGF), and Activin A (Figure 4.5). Additionally two 
proteins, TIMP metallopeptidase inhibitor -1 (TIMP-1) and plasminogen activator 
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inhibitor (PAI-1), which have been associated with a decrease in left ventricular 
remodeling and cardiac fibrosis post-MI, and thrombospondin-1 (TSP-1), which is 
a known anti-apoptotic cytokine (Table 4.2). These results suggest that several 
pathways might be collaborating to the potential cardiotherapeutic properties of 
the encapsulated cells. 
 
We focused on one protein, VEGF, to test the difference in secretion levels of 
constructs with differing diameter and cell density. As expected, there is an 
increase in secretion in relation to number of cells encapsulated for all 
microchannel diameter conditions (Figure 4.6). When comparing microchannel 
diameters to one another, we found that the secretion level was statistically 
indistinguishable between the patches that contained no microchannels and 
those with 500µm diameter microchannels, however, there was a distinct drop in 
secretion from the patches containing 1000µm diameter microchannels. This 
presumably is due to the relative number of cells within the patches, and the 
decrease in cell number that accompanies the incorporation of a channel that 
cuts through the patch itself. To test this hypothesis, we normalized the secretion 
levels to the calculated cell number within each patch. This normalization brought 
all secretions levels to a more comparable level. Again, no significant difference 
was seen between the zero and 500µm microchannel diameters, however, the 
1000µm still shows a lower, and statistically significant, secretion rate than the 
500µm condition, suggesting a diminishing return of cytokine secretion in regards 
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4.4.3 Controlled vascularization via microchannel incorporation 
To assess their vasculogenic capabilities, the constructs were placed on a chick 
chorioallantoic membrane (CAM). At 10d post-transplantation, a clear, directed 
neovascularization was seen at the location of the microchannels in the patches 
containing 500µm diameter microchannels, a phenomenon that diminishes when 
the microchannel diameter is increased to 1000µm (Figure 4.7). While blood 
vessels were indeed seen on the CAM of samples containing 1000µm 
microchannels, the vessels were much smaller and more immature than those 
seen in constructs with either no microchannels or 500µm microchannels. 
 
After imaging, the construct-containing region of the membrane was dissected 
and fixed for further histological analysis. The sections were stained with α-
smooth muscle actin to identify vessels within the membrane. The area directly 
below the construct was isolated and vessels with an area of 50µm2 or greater 
were counted. A clear increase in overall vessel area density was seen with 
increasing cell numbers (Figure 4.8). Observing the vessel density difference 
between microchannel diameter, holding the cell number constant, the highest 
density is seen in constructs of 500µm diameter, with a density decrease when 
the microchannel diameter was increased to 1000µm. These results indicate, as 
suggested by the secretion profile, show diminishing returns of microchannel 
incorporation when the diameter is increased to 1000µm, independent of the cell 
density that is contained within the hydrogel patch. Interestingly, while VEGF 
secretion between no microchannels and 500µm microchannels is not 
significantly different, there does seem to be a trend in increasing vessel density 
with the incorporation of the channels, suggesting that that concentration of the 
soluble factors might play a role in the vasculogenic capabilities of the construct. 
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4.4.4 Mouse MI model 
A mouse myocardial infarction model was used to test the efficacy of the 
microchannel containing hydrogel patch in helping to cease the remodeling of the 
heart following ischemic injury. The left coronary artery was occluded to mimic 
the blockage of blood flow to the left ventricle that is characteristic of the majority 
of myocardial infarctions. A blanching of the myocardium downstream of the 
occluded vessel can be seen almost instantaneously, aiding in the identification 
of the effected tissue. Immediately following the occlusion, the patch was placed 
directly on the ischemic tissue, and a fibrin-based glue was applied to the exterior 
of the patch to ensure adherence to the myocardium (Figure 4.9). 
Echocardiogram measurements were then performed to analyze the heart 
function with and without treatment. 
  
4.4.5 Induction of MI 
The initial LAD occlusion resulted in a significant drop in both the ejection fraction 
(from 60.7%±9.2% to 15.9%±11.0%), the fractional shorting (from 31.2%±6.2% to 
7.2%±5.0%), and the stroke volume (from 27.7%±6.2% to 13.7%±6.6%) (Figure 
4c, d, e). Histological analysis of the excised hearts showed a marked dilation of 
the left ventricular diameter with increase in luminal volume and diameter, and 
ventricular aneurysms with a decrease in left ventricular wall thickness along with 
collagen deposition at the site of ischemia, confirming positive infarction induction 
and scar tissue deposition. 
 
4.4.6 Treatment of MI 
Following initial in vitro experiments, it was concluded that the efficacy of the 
500µm microchannel diameter constructs would be tested in both lower and 
higher cell concentrations. The lack of angiogenic potential of the 1000µm 
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microchannel diameter constructs negated any further in vivo testing. To 
maintain the focus of the efficacy of the patch on secreted cytokines, rather than 
on transplanted and integrated cells, the no diameter patch was also kept out of 
in vivo testing.   
 
Patches were placed on the heart directly following LAD ligation. 
Echocardiograph measurements taken 4-5wks post-operatively showed a 
significant increase in the ejection fraction and stroke volume of hearts treated 
with a cell-encapsulated patch. Although not statistically significant, a step-wise 
improvement was noticed with an increase in cell density. Patches containing no 
cells displayed cell function similar to the MI only group, confirming that the cells 
within the construct are responsible for cardiac protection, and not the presence 
of the construct itself (Figure 4.10). 
 
Animals were sacrificed at 8wk to visualize the cellular and morphological 
changes attributed to the treatment. Histological analysis showed that the 
patches containing a low density of cells caused a slight decrease in cardiac 
fibrosis with a decrease in left ventricular dilation, while animals treated with the 
high density cell construct showed very little necrosis at the site of injury with little 
to no ventricular dilation and wall thinning, as well as an increase in 
neovascularization. This was in clear contrast with the untreated animals where 
left ventricular dilation, wall thinning, and clear collagen deposition and fibrosis 
are seen (Figure 4.11). Together, all these results are characteristic of 
cardiomyocytes necrosis and scar tissue formation. Animals exposed to a patch 
with no encapsulated cells showed similar results as untreated animals. 
Quantitatively, these results can be summarized by the left ventricular and septal 
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thicknesses, which, when normalized to the ventricular diameter, both showed an 
increase compared to the negative controls (Figure 4.11).  
 
4.5 Discussion 
We have shown that MSCs can be maintained within a PEGDMA hydrogel 
construct without losing their ability to secrete beneficial cytokines to its 
surroundings. The growing body of knowledge suggests that stem cell treatment 
for cardiovascular disease is dependent more on the secretion of soluble factors 
from the cells rather than direct differentiation of the cells. By controlling the 
environment and delivery of these cells via user-generated 3D manipulation of 
the vehicular constructs, we can further increase their therapeutic potential. In 
previous studies, we have established that the introduction of microchannels 
produces “wells” of concentrated secreted cytokines. This concentration in turn 
allows for greater, and directed, angiogenic potential at the site of the 
microchannels36. Although an MSC containing hydrogel construct has been 
shown to improve heart function by a number of other groups, we hypothesize 
that the added benefit of controlled vascularization restores the heart to within 
reach of its pre-MI state. 
 
Upon analysis of the histological sections obtained at 8wk post-implantation, the 
animals that either received no patch or a blank patch without cells showed no 
inflammatory response at the site of injury. When cells were added as a 
treatment, florid inflammatory reactions were still present 8wk post-operatively. 
This finding suggests that the prolongation of the inflammatory process in the 
treated animals, as well as the increase in neogenesis, are two contributing 
mechanisms to the protection of the myocardial muscle from the effect of post-MI 
fibrosis. Whereas terminal scar formation was seen in animals that received no 
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treatment, a robust immune response was still present with the addition of stem 
cell therapy, prolonging the window of opportunity to cease or reverse the 
negative effects of the hypoxic environment on the cardiomyocytes.  
 
With this design, we have also shown the importance of cell density when 
conducting these studies. While most groups use a cell density of 1x106 
cells/condition or more, we cut this amount drastically, with our most beneficial 
patches containing only 7,100 cells. This drastic decrease in cell number might 
help alleviate the translational burden of collecting and culturing MSCs for clinical 
use. 
 
Utilizing an established stereolithography apparatus, we have developed a 
platform in which complex, three-dimensional, cell encapsulated structures can 
be fabricated. We have previously shown that fibroblasts can both remain viable 
and secrete factors for up to 7d post encapsulation35. Additionally, the user-
controlled nature of the platform was utilized to incorporate microchannels into 
the cardiac patch. These channels serve as a well for soluble factors to 
congregate within, increasing the surface area available for release of these 
beneficial factors, and in turn, increasing the angiogenic potential of the patch 
and allowing for directed neovascularization at the site of the microchannels36. 
This hydrogel system provides a means to deliver the therapeutics to the site of 
injury, introducing the prospect of using the material for treatment of ischemic 
heart failure. Through the replacement of fibroblasts with MSCs, we can deliver 
cells that have been proven successful in post-MI therapy directly to the site of 
infarction, while ensuring maximum soluble factor secretion at the site of injury 
via microchannel incorporation. This would thus provide a cytokine driven 
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therapeutic approach to aid in the prevention of detrimental heart remodeling 
following a myocardial infarction. 
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4.6. Figures and Tables 
 
 
Figure 4.1: Schematic representation of the stereolithography apparatus 
(SLA) procedure. A 3D computer aided design (CAD) is developed and 
converted into the stereolithography format. The SLA then focuses a UV light 
source on a cell-containing pre-polymer solution. The focusing of the light results 
in cross-linking and subsequent encapsulation of the cells in the pre-defined 
design. 
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Figure 4.2: Construct designs and microchannel diameters. Three designs 
were chosen, one lacking microchannels, and two with 9 evenly spaced 
channels, one of 500µm in diameter, and another of 1000µm diameter. Each 
construct, aside from the blank controls, contained encapsulated cells that were 
“trapped” within the crosslinking PEGDMA. 
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Table 4.1: Conditions used throughout the experiment. A total of 9 conditions 
were tested. Each construct was delineated by three different microchannel 
diameters (0µm, 500µm, and 1000µm) as well as three different cell 
concentrations (no cells, 0.4x106 cells/mL, and 2.0x106 cells/mL). 
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Figure 4.3: Cell viability in the constructs post-encapsulation. MTT data 
taken at days 1, 3, 5, and 7 from constructs with 500 µm diameter microchannels 
and high cell density show sustained viability for up to 3d post-encapsulation, at 
which point relative cell viability decreases within the patch. By day 7, the 
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Figure 4.4: Live and dead cell imaging of encapsulated cells. Live/dead 
analysis of constructs containing high density of cells show a relative high 
percentage of dead cells within the patch at day 1. Instead of an increase in dead 
cells, as would be expected, there seems to be a leakage of cells from within the 
patch to the surrounding area by days 7 and 14, evident by the change of some 
live cells into fibroblast-like morphology that is typical of plastic adherence of 
MSCs. 
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Figure 4.5: Paracrine factors secreted by encapsulated cells. An 
angiogenesis antibody array was used to detect the relative levels of cytokines 
secreted out of a 500µm microchanneled construct containing a high cell density. 
Of the 55 angiogenesis-related proteins present on the membrane, 12 could be 
detected. The action of these cytokines range from potent promoters of 
angiogenesis to inhibitors of cardiac remodeling.   
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Cytokine Function 
Activin A Increases expression level of type-1 collagen.  
IGFBP-1, 3 Lengthens half-life of circulating IGF in tissues. 
IL-8 Potent promoter of angiogenesis. 
MMP-9 Promotes cell metastasis from the bone marrow. ECM protease. 
PTX-3 Anti-apoptotic 
PAI-1 Blocks effects of uPA, decreases cardiac fibrosis 
PEDF Inhibitor of angiogenesis 
TIMP-1 Decreases LV remodeling 
TSP-1 Antiapoptotic 
uPA Promotes plasminogen to plasmin conversion for ECM breakdown 
VEGF Promoter of angiogenesis 
 
Table 4.2: Brief description of proteins secreted from MSC encapsulated 
patch 
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Figure 4.6: Cells within the patch show sustained secretion of paracrine 
factors for up to 7d post-encapsulation. Focusing on a single secreted 
cytokine (VEGF), a distinct increase in secretion was seen with an increase in 
encapsulated cell number for all three microchannel diameter conditions (a). The 
disparity seen between the 1000µm microchanneled patches and those of the 
500µm and no microchannel patches are quite large, however, the differences 
diminish when the secretion levels are normalized to number of cells 
encapsulated within the patch (b). 
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Figure 4.7: Directed vascularization of cell encapsulated constructs with 
500µm diameter microchannels. Brightfield images of construct containing 
CAM 10d post-implantation show distinct neovascular structures at the site of 
500µm microchannels. This phenomenon is diminished when the microchannel 
diameter is increased to 1000µm.  
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Figure 4.8: Vessel density differences between hydrogen construct 
conditions and cell densities. Construct containing portions of the CAM were 
excised, sliced, and stained to quantitatively determine vessel densities. Vessels 
of 50µm2 were counted, and an increase in vessel density was seen with 
increasing cell numbers within the constructs. When comparing microchannel 
diameters in constructs containing high cell density, we again saw the greatest 
number of vessel density in constructs with 500µm microchannels, with lesser 
numbers in the no-channel containing and 1000µm channel constructs. 
Constructs made of 500µm microchannel diameter and high cell concentration 
showed the greatest vessel density. Representative images of stained CAM are 
shown below their respective quantitative data bars. Asterisks (*) represent 
statistical significance of p = 0.5. 
 
  




Figure 4.9: Patch placement on the murine heart post-MI induction. A live-
image of the final placement of the construct on the epicardial surface of the 
heart clearly shows the suture placement directly below the left atrium and the 
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Figure 4.10: Cell encapsulated patches improve cardiac function post-
infarction. Echocardiogram measurements show a comparative measurement of 
cardiac function between animals receiving no treatment (MI only) and those with 
constructs containing no cells (Blank). The addition of a small amount of cells 
(low) showed significant improvement over controls, but the greatest difference 
was seen when a higher concentration of cells was added to the construct (high). 
Results from the higher cell density constructs are nearing those of healthy 
controls (No MI). Asterisks (*) represent statistical significance of p = 0.5.   
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Figure 4.11: Cell encapsulated patches show a decrease in left ventricular 
remodeling 8wks post-infarction. Representative 8wk histological images of 
each condition  are shown along with their respective functional measurements 
(a). The constructs can clearly be seen, and a decrease in fibrosis and collagen 
deposition (blue staining) can be appreciated with increasing cell densities. 
Quantitative analysis of left ventricular free wall thickness (b) and septal 
thickness (c) normalized to the overall heart diameter show an increase in each 
with the addition of cells to the constructs, indicating a decrease in myocardial 
remodeling.  
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5. SUMMARY, ONGOING WORK, AND FUTURE DIRECTIONS 
 
5.1 Summary 
As highlighted throughout this dissertation, we have developed a stem cell 
centered cardiac patch that, when delivered to the site of injury, helps to 
decrease cardiac fibrosis and improves cardiac function post myocardial 
infarction assault. Cardiac tissue engineering is an emerging field, with a number 
of current and ongoing studies being done to determine the best scaffold, cell 
type, and delivery method to treat alleviate cardiac remodeling and degeneration. 
While this project is just a piece of the larger picture, I believe it provides a 
number of benefits over similar studies.  
 
One such advantage is the use the non-immunocompetent mice in our studies. 
Many groups that have shown a decrease in cardiac fibrosis in fact ran their in 
vivo tests in severe combined immunodeficiency mice or nude rats1-3. While 
these studies provided a necessary baseline and framework for future studies, 
they also must be approached with some level of caution since the introduction of 
lymphocytes and the complete complement system might alter the animal’s 
response to therapy. By using C57BL/6J mice, we have removed the question of 
immune response from any final conclusions we can make about the 
effectiveness of our constructs. 
 
Another benefit of our model is the overall number of cells that were used and 
delivered to the heart wall. We chose to encapsulate a much smaller number of 
cells, between 1,400 to 7,000, within each construct, as opposed to almost every 
other study that encapsulated or delivered 1x106 cells (see Chapter 1 for related 
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citations). This drastic decrease in the number of cells might possibly alleviate 
the burden or necessity of isolating and expanding stem cells if/when this 
technique arrives in the clinical setting. 
 
Finally, we utilized the control that the SLA provides to incorporate 
microchannels within our constructs. These channels increased the surface to 
volume ratio of the hydrogels, allowing for greater secretion of paracrine factors, 
and subsequently increased the vascularization potential of the encapsulated 
cells.  
 
5.2 Ongoing Work and Future Directions 
5.2.1 Unveiling the underlying mechanisms of BM-MSC protection 
Overview: One major question that still needs to be addressed is the exact 
mechanism that accounts for the protection attributed to the BM-MSC therapy. 
There has been plenty of work in the field to attempt to answer this question, with 
a number of possible theories emerging. The pathway most attributed to 
cardioprotection is that of the phosphoinositide 3-kinase (PI3K)/Protein kinase B 
(AKT) pathway4-7. The activation of the pathway may be from a variety of 
mechanisms. Some suggest integrin-linked kinase (ILK) might play a role in AKT 
activation, while others point to a protein complex that consists of growth factor 
receptor-bound protein 2 (Grb2), focal adhesion kinase (Fak), the proto-
oncogene tyrosine-protein kinase Src (cSrc), and a specific subunit of PI3K 
(PI3K-p85)5,7,8. No matter the mechanism, activated AKT is thought to activate 
the protein complex known as nuclear factor kappa-light-chain enhancer of 
activated B cells (NFκB) which has a direct result of regulating genes involved in 
cell survival5. AKT can also concurrently block the phosphorylation of Bcl-2-
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associated death promoter (BAD), caspase 9, and forkhead transcription factors, 
slowing down their associated apoptotic pathway7.  
 
Determining the mechanistic properties of our cardiac patch: Seeing as there are 
a variety of mechanisms that might play a role in MSC protection, it would be 
beneficial to add our own piece of information into the growing body of 
knowledge. Future work can be done to strengthen the model highlighted in this 
dissertation by providing a more detailed view of the pathways associated with 
the pro-angiogenic and survival results that we highlighted with the patch 
therapy.  
 
5.2.2 Stromal derived factor-1 (SDF-1) incorporation within the construct 
Overview: The body naturally tries to prevent the degradation of heart tissue 
following an MI event via the recruitment of BM-MSCs or similar stem cells 
through cytokine secretion. A number of cytokines and enzymes have been 
suggested to play a role in the recruitment of stem cells to the damaged tissue 
site including, interleukin’s -1, -6, and -8 (IL-1,-6,-8), granulocyte colony-
stimulating factor (G-CSF),  transforming growth factor-β (TGF-β) matrix 
metalloproteinase’s (MMP’s), and elastases9-12. A growing body of evidence 
suggests that SDF-1 plays the most prominent role in the homing of stem cells 
that express the CXCR4 ligand13-17. We have hypothesized that a patch doped 
with stem cell homing factors, specifically SDF-1, may provide a means to 
upregulate the naturally occurring homing mechanisms of stem cells. If proven 
successful, this doped patch can be placed similarly to our cell encapsulated 
patch, but instead of therapy by an external cell population, we would be able to 
utilize the body’s own resident stem cells for protection and regeneration post-MI. 
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Fabrication of an RGD-alginate gel: Alginates are polysaccharides that are 
naturally found in algae, and are widely used to encapsulate a number of 
different cells types in the field of bioengineering (refer to Chapter 1 for more 
details)18,19. Cells do not attach to alginate itself, thus, a bioactive peptide must 
be added to promote attachment of cells to the construct20,21. For these 
purposes, we have added an RGD peptide to the alginate backbone to promote 
cell retention after mobilization to the patch. 
 
Creation of horizontal microchanneled, cell capturing gels: Mimicking similar work 
done in our lab, horizontal microchannels were incorporated into a hydrogel 
patch the patch to increase the surface area available for cytokine secretion and 
direction vascularization in a parallel fashion22. Using a copper plate cooled by 
liquid nitrogen, the patches were placed on their edge, such that directional 
freezing was achieved within the patch (Figure 5.1). This directional freezing 
created ice channels of, on average, 100µm in diameter. The patches were then 
lyophilized, allowing for the ice columns to dissipate and leave behind horizontal 
microchannels of approximately the same diameter.  
 
Incorporation of SDF-1 PLGA microparticles: Previous work in our lab has 
focused the incorporation of drug-releasing poly(lactic-co-glycolic acid) (PLGA) 
microspheres within cell-encapsulating gels23. These microparticles are small 
enough to not interfere with the integrity of the gel, but allow the inclusion of 
desired materials via a permeable vehicle. Microparticles of 1-30µm in diameter 
containing SDF-1 were prepared using a double emulsion/evaporation process 
and incorporated into hydrogel patches. The goal was to utilize these 
microparticles as a module to systematically deliver SDF-1 to the surrounding 
tissue, creating a gradient that would encourage stem cells to home to the patch. 
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SDF-1 was encapsulated within the PLGA microparticles and secretion from the 
particles was tested and proven positive (data not shown). These particles were 
then added to a pre-polymer solution and incorporated into our hydrogel 
constructs. 
 
As stated, the constructs were either directionally freeze dried to introduce 
horizontal microchannels, or simply placed in liquid nitrogen to produce a 
microporous structure. The patches were then dehydrated via lyophilization, and 
imaged under a scanning electron microscope (SEM) to determine the 
construct’s topology and composition. The introduction of horizontal 
microchannels can be appreciated as a smooth groove within the construct, while 
the PLGA microparticles can clearly be recognized as beaded structures 
throughout the construct (Figure 5.2 a,b). In contrast to the microchanneled 
topology, the microporous structures showed a randomized linking within and 
around the PLGA microparticles (Figure 5.2 c).  
 
SDF-1 secretion from the constructs: While we were able to identify PLGA 
microsphere’s within the construct there was no trace of SDF-1 secretion upon 
re-hydration of the patch, despite the detection of SDF-1 secretion out of the non-
encapsulated PLGA microparticles (Figure 5.3). In an attempt to address this 
issue, the lyophilized patches were re-hydrated with a 100µg/mL solution of SDF-
1 for 10min, followed by emersion in media that was changed and collected at 
varying time points. With this method, SDF-1 secretion was observed and 
maintained for up to 7d, providing a possible avenue for SDF-1 secretion in 
future studies (Figure 5.3). 
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Homing of autologous stem cells to the construct: By providing a means of 
releasing SDF-1 from our constructs into the surrounding tissue, we aim to 
enhance the natural SDF-1 gradient that is responsible for stem cell homing to 
the site of injury, and naturally observed in the myocardium post-MI. To test the 
ability of our patches to attract stem cells, the constructs that either contained 
SDF-1/PLGA microspheres or were rehydrated with SDF-1 cytokine were 
incubated atop an MSC-containing collagen gel. After 10d of incubation, we 
excised the patch and imaged the cells with confocal microscopy. The patches 
that showed constitutive secretion of SDF-1 from the patch (those that were 
rehydrated with SDF-1) interestingly showed less migration to, and adhesion 
onto, our constructs than those that did not appear to secrete any detectible 
amount of cytokine into the surrounding medium (Figure 5.4). Although it requires 
further work to test the hypothesis, one possible explanation relates to the 
concentration gradient created by the constructs: If SDF-1 is released very 
actively into the surrounding environment, cells will not be stimulated to home to 
the material due to a lack of concentration gradient. In contrast, with localized 
secretion from the PLGA particles into just the construct of the environment, the 
cells can be signaled to home to within the construct. In other words, an increase 
in secretion of SDF-1 into the surrounding tissue obliterates the gradient that is 
needed for chemotaxis, whereas a localized release confined to the construct 
alone will allow for stem cell homing and mobilization to the construct itself. 
 
With this preliminary data, we envision the incorporation of SDF-1 into a 
bioengineered construct to promote the enhancement of stem cell recruitment to 
the site of injury, embellishing the body’s natural mechanism of cardiac protection 
via stem cell mobilization. 
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5.2.3 Greater control through emerging micro-SLA technology 
Overview: Work is actively being done to scale-down the resolution capabilities of 
the SLA to a nanometer scale. This capability will open the door for even greater 
control of the construct, including the ability to incorporate more accurate designs 
within the patch. 
 
Creating vascular gradients: Greater control of the patch morphology and 
structure allows for a wide range of future possibilities. One vision would be the 
introduction of a gradient of nano- and micro-channels. As such, we can promote 
vascularization at the border zone first, with smaller and more densely populated 
nanochannels, and gradually increase the diameter and decrease the density of 
the channels, promoting the merging of smaller vessels into larger ones that can 
help sustain the myocardium. In such a way, we can address the gradient of 
necrosis that is observed in post-MI hearts. 
 
Altering the 3D microenvironment: We can further use the micro-SLA to alter the 
environment within the hydrogel system, possibly by incorporating support cells, 
cytokine containing microparticles, or different scaffolding materials within the 
patch. As it stands, our constructs are made of a single material, PEGDMA, 
however, it has been documented that the 3D environment in which cells are 
grown alters their proliferation and secretion properties24,25. The micro-SLA 
platform will afford greater capability to alter and regulate the cell binding 
properties and characteristics that accompany different scaffold properties. 
Additionally, through the incorporation of support cells and/or cytokine containing 
microparticles, we can further control the secretion and growth properties of the 
encapsulated cells. 
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5.2.4 Less-invasive patch delivery via a self-unrolling patch 
Overview: Work has emerged from our group demonstrating the ability to 
manipulate hydrogel gels to produce constructs that self-fold26. By pairing layers 
of poly(ethylene glycol) diacrylates of different expansion ratios and elastic 
moduli, self-folding can be accomplished thanks to the different absorption 
properties of the two layers. Moreover, constructs were altered as such that one 
layer secreted encapsulated cytokines, while the other did not, resulting in 
directional delivery of incorporated cytokines. 
 
Laparoscopic patch delivery with directed cytokine delivery: Utilizing the same bi-
layer approach, it is hypothesized that we can create a patch that unfurls upon 
contact with the heart surface. With this technology, a patch can be rolled into a 
thin cylinder, and placed within a needle or other delivery device to be delivered 
via conventional laparoscopic surgery. This approach would provide a non-
invasive delivery method, addressing concerns of clinical translation of our 
hydrogel construct. In addition, the directed delivery that was detailed in the 
preliminary study could translate into a sustained release out of one surface of 
our patch, that which is closest to the heart. This would result in a sustained 
release towards the heart only, instead of our current construct, which doesn’t 
delineate the direction in which soluble factors diffuse out. 
 
5.2.5 Large animal stem cell mobilization 
Overview: The pig is an excellent pre-clinical model for a variety of procedures, 
diseases sates, and damage models (see Chapter 1). The biological similarities 
between pigs and humans are numerous and include similar organ to body 
weight ratio, heart physiology, and reproductive organs. Porcine models have 
been developed to test tissue engineering for skeletal defects, myocardial 
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infarction treatment, and skin defects. Additionally, with the sequencing of the 
entire porcine genome, we are able to integrate comparative genomics into 
clinical outcomes and physiological responses to a variety of different treatments 
in the pig. Overall, there is a great therapeutic potential in the use of the pig as a 
pre-clinical animal model. Despite this promise the identification and 
characterization of porcine stem cells in hampered by a lack of commercial 
reagents and antibodies.  
 
Hematopoietic stem cells are chosen as a therapeutic cell type to treat a number 
of human diseases. They are capable of repopulating the blood and immune 
system, making them a likely candidate for cell transplantation, and they are 
known to produce beneficial growth factors and cytokines, a trait of critical 
importance for clinical therapeutics. Release of hematopoietic stem cells into the 
periphery, termed mobilization, is a naturally occurring phenomenon that can be 
reproduced clinically by a number of cytokines, chemokines, and 
chemotherapeutics (Table 5.1)9-11,27. While early bone marrow transplants 
required invasive procedures to collect the stem cell containing bone marrow of 
donors, new technologies often rely on this simple mobilization of stem cells from 
the bone marrow niches into the blood stream. Once present in the peripheral 
blood, simple collection and isolation techniques allow for relatively pain free 
isolation of the cells that can then be injected into the recipient patient. In the 
clinic, one of the most widely used mobilization techniques is the chemical 
induction by granulocyte colony stimulating factor (G-CSF). G-CSF act to cleave 
the stem cells from their niche within the bone marrow and migrate into the 
surrounding vasculature. While the use of G-CSF is the standard method of 
collection of human hematopoietic stem cells, a pig specific form of the growth 
factor has yet to be available commercially. 
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Mobilization and collection of pig HSCs: Our group has developed a pig specific 
G-CSF protein that, when injected into the bloodstream, shows mobilization of 
cells almost immediately, with sustained mobilization for up to 4d post-injection 
(Figure 5.5). Moreover, we have shown an increase in both white blood cell 
counts and CD34+ (hematopoietic stem/progenitor) cells in response to 
Plerixafor (AMD3100), the CXCR4 blocking drug, mobilization that has not 
previously been performed in pigs before (Figure 5.6). Equipped with ability to 
mobilize stem cells in the pig, we have the ability to collect and encapsulate 
autologous stem cells for a large animal model.  
 
5.3 Cardiac Patch Outlook 
Taken together, the suggestions above paint a rather exciting future for the 
cardiac hydrogel construct: 
 
1) The microSLA technology will allow us to better control the designs being 
incorporated into the patch. With this, we can test better techniques to 
promote vascularization in a small animal model. Furthermore, by better 
understanding the mechanisms of stem cell protection, we can enhance 
the construct, either by the addition of supporting cells or by the 
encapsulation of specific cytokines, to upregulate the desired survival and 
angiogenic pathways that are already being tapped into. 
 
2) The incorporation of SDF-1 into a patch construct will allow the natural 
recruitment of therapeutic stem cells from the body into the patch. With 
this, we envision a construct that contains both therapeutic stem cells as 
well as SDF-1 secreting microparticles. This would allow the encapsulated 
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cells to immediately perform their angiogenic and survival capabilities, 
while the addition of SDF-1 would enhance stem cell recruitment and 
homing to the site of injury, providing a second manner of therapeutics 
that relies on the body’s natural ability to fight the negative effects of 
hypoxic injury. 
 
3) Large animal stem cell mobilization, paired with the SDF-1 doped patch, 
allows for a full model for autologous stem cell therapy without ever having 
to extract, isolate, expand, and re-introduce the cells into the body. The 
self-unrolling technology developed in our lab recently will further 
decrease the invasiveness of the procedure, allowing for laparoscopic 
delivery of our patch to the animal. If proven successful, such an approach 
would be the least-invasive and quickest model for stem cell driven 
cardiac treatment. 
 
5.4 Materials and Methods 
5.4.1 PLGA microparticles 
SDF-1α encapsulating PLGA microparticles were prepared by a water-in-water 
double emulsification method. A 100ug/mL stock solution of SDF-1α (R&D 
systems) was further diluted in 50µL PBS to create a final concentration of 
0.1µg/mL. This solution is referred to as the initial water phase (W1). 
Concurrently, 0.1g of PLGA (Sigma-Aldrich) was dissolved in 1mL of 
dichloromethane, a phase termed the oil phase (O). The primary emulsion was 
obtained by mixing W1 with O, followed by a 20s vortex. The resulting emulsion 
was poured into a 0.1 (w/v) aqueous poly(vinyl alcohol) (Sigma-Aldrich) solution 
(W2 phase) and stirred vigorously for 4h under a hood to allow the 
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dichloromethane to evaporate. The resulting solution should now consist of the 
SDF-1α containing microparticles in an aqueous solution. The solution is placed 
in a lyophilizer overnight to dry out the microparticles. For microparticle 
encapsulation into a hydrogel construct, the PLGA microparticles were dispersed 
in the pre-gel solution at a concentration of 1% (w/v) prior to the hydrogel-forming 
crosslinking reaction. 
 
5.4.2 Microchanneled and microporous alginate hydrogels 
Alginate gel manufacturing and microchannel/micorporous structure integration 
were performed following previously published protocols22. In brief, Microparticle 
encapsulating RGD-Alginate gels were produced by mixing PLGA microparticles 
sulfonated N-hydroxysuccimide (Sulfo-NHS; Thermo Scientific), adipic acid 
dihydrazide (AAD; Sigma-Aldrich), and 1-ehtyle-3-(3-
dimethylaminopropyl)carbodiimide (EDC; Thermo Scientific). The pre-gelled 
mixture was spread between two glass plates with a 1mm spacer in between. 
Once gelled, disks of 5mm in diameter were punched out and incubated in DI 
water at room temperature overnight. To create the horizontal microchannels, the 
constructs were precariously placed on their edge atop a copper plate that whose 
temperature was decreased to -196oC by liquid nitrogen to induce column growth 
throughout the patch. Constructs with micropores, as opposed to microchannels, 
were not directionally frozen, but rather exposed to liquid nitrogen by direct 
submerging. All frozen gels were then lyophilized overnight to evaporate any 
aqueous solution within the gel and create the final microporous or 
microchanneled structures. When needed, the dehydrated gels were re-hydrated 
by the addition of aqueous solutions. 
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5.4.3 SDF-1α secretion studies 
Dehydrated gels were rehydrated with 10µl of either a 100µg/mL solution of SDF-
1α (R&D systems), or sterile 1x PBS. Gels were left to rehydrate for 10m, after 
which time aqueous media was added to the constructs. Media was collected 
and changed at the 30m time point, as well as every consecutive day for a total 
of 7d. An SDF-1α ELISA (R&D Systems) was then run on the samples following 
the manufacturer’s protocol. 
 
5.4.4 Cell migration studies 
Constructs were embedded into a cell containing collagenous gel to test the 
ability of SDF-1 doped constructs to promote cell migration into the patch. D1 
mouse MSC’s were re-suspended in culture media at a concentration of 5x104 
cells/mL. The cell containing media was then added to the collagen (Pure Col; 
Advanced BioMatrix) in a 1:1 ratio. Patches were immediately placed on the 
solution following mixing and incubated for 2h at 37oC 5% O2. Following the 2h 
incubation, warm media was added to the now-gelled cell containing collagen 
solution and incubated. Cells adhered to the construct were stained by 
fluorescent phallodiin and DAPI to image their actin filaments and nuclei, 
respectively. Constructs were then imaged with a laser scanning confocal 
microscope (Leica, LSM700). 
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5.6 Figures and Tables 
 
 
Figure 5.1: Creation of micro-grooves within hydrogels. Horizontal 
microchannels can be incorporated within hydrogel constructs by directing the 
freezing of ice crystals. By laying the constructs on their edge atop a copper plate 
cooled with liquid nitrogen, the crystals begin to form at the contact point and 
freeze upwards. Here you can see the frontline of the directed freezing. 
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Figure 5.2: Incorporation of PLGA microparticles. Cytokine containing 
microparticles are encapsulated within the hydrogel structure in much the same 
way cells were encapsulated in earlier experiments (Chapter 4). SEM images of 
a micorchanneled gel with no microparticles (a) show distinct grooves without 
any interfering structures, in contrast to the a microchanneled gel with PLGA 
microparticles incorporated within it (b). A PLGA encapsulating gel that lacks the 
distinct horizontal microchannels is porous in nature, with indiscriminate 
crosslinking throughout (c). 
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Figure 5.3: SDF-1 secretion from re-hydrated and PLGA containing 
constructs with and without horizontal microchannels. The secretion of 
SDF-1 from constructs with either bulk SDF-1 (SDF) or SDF-1 contained in 
PLGA microparticles (PLGA) were tested for their secretion profiles. Rehydration 
with bulk SDF-1 showed a constitutive secretion into the surrounding media, in 
stark contrast to the constructs encompassing SDF-1 containing PLGA 
microparticles, which showed no detectible secretion into the surrounding media. 
Further delineation was made between microchannel incorporation (MC) or 
microporous structures (MP), showing no difference in secretion between the two 
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Figure 5.4: SDF-1 upregulates stem cell mobilization in vitro. Microporous 
and microchanneled constructs with either bulk SDF-1 or SDF-1 containing 
microparticles were placed on an MSC-seeded collagen gel to test their ability to 
mobilize stem cells to wihin the patch. Confocal images taken 10d after 
implantation show directed mobilization in all microchanneled constructs, with the 
greatest concentration of cells seen in constructs containing the SDF/PLGA 
microparticles (a). Quantitative analysis further verifies that the presence of 
SDF1/PLGA microparticles increases cell mobilization into the constructs (b). 
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Designation Molecule 
Cytokines G-CSF, GM-CSF, IL-3, IL-12, SCF 
Chemokines SDF-1, IL-8, MIP-1α, GROb 
Chemotherapeutics Cyclophosphamide, Paclitaxel, Plerixafor 
Table 5.1: Molecules attributed to stem cell mobilization 
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Figure 5.5: G-CSF mediated cell mobilization in a porcine model: Porcine 
specific G-CSF was administered as a bolus injection to assess the functionality 
of the species-specific cytokine. Two separate concentrations were administered, 
alongside a negative control of 1xPBS injection. Subsequent leukophoresis was 
performed over a 4d timecourse and a white blood cell count was obtained. 
Results show a clear increase in mobilization of cells from the bone marrow into 
the surrounding circulation with each dose administered, with the greatest 
mobilization seen at 10µg/kg concentration 24h after initial injection. 
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Figure 5.6: Dose response of AMD3100 in cell mobilization. AMD3100 was 
administered in three different doses to three different pigs. A leukapheresis 
machine (COBE Spectra) was used to collect large numbers of white blood cells 
(WBCs) after mobilization. A marked increase in WBCs was seen in a dose 
dependent manner (a). The serum was then tested for the presence of the stem 
cell marker CD34, the same dose dependent response was seen (b), suggesting 
that along with the overall WBC response, mobilization with AMD3100 triggered 
a subpopulation of stem cells into the peripheral blood.  	  
